CLINICAL STUDY PROTOCOL
Study Title: A Phase 1 Open -Label, Parallel -Group, Adaptive, Singl e-Dose 
Study to Evaluate the Pharmacokinetics and Pharmaco dynamics of 
GS-9674 in Subjects with Normal and Impaired Hepatic Function
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
IND No.: 127960
Clinical Trials.gov
Identifier:[STUDY_ID_REMOVED]
EudraCT No.: Not Applicable
Indication: Nonalcoholic Steatohepatitis (NASH)
Protocol ID: GS-US-402-3885
Gilead 
Medical Monitor Name:
Telephone:
Fax:
Mobile :
Protocol Version/Date: Original : 03 May  2016
Amendment 1: 29 July  2016
Amendment 2: 23March 2018
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The information is only  to be used by  you in 
connection with authorized clinical studies of the investigatio nal drug described in the protocol.
You will not disclose any of the information to others without written authorization from Gilead 
Sciences, Inc., except to the extent necessary  to obtain informed consent from those persons to 
whom the drug may  be admini stered.
PPD
PPD
PPD
PPD
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 2 23March 2018TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ........................................................................................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 17
1.1. Background ............................................................................................................................................ 17
1.2. GS-9674 ................................................................................................................................................. 18
1.2.2. Preclinical Pharmacology, Pharmacokinetics and Toxicology ............................................. 18
1.2.3. Nonclinical Pharmacology ................................................................................................... 19
1.2.4. Nonclinical Pharmacokinetics .............................................................................................. 20
1.2.5. Clinical Trials of GS -9674 ................................................................................................... 21
1.3. Rationale for This Study ........................................................................................................................ 25
1.3.1. Rationale for the Dose Selection .......................................................................................... 26
1.4. Risk/Benefit Asses sment for the Study .................................................................................................. 26
1.5. Com pliance ............................................................................................................................................ 27
2. OBJECTIVES ................................
..................................................................................................................... 28
3. STUDY DESIGN ................................................................................................................................................ 29
3.1. Study Design .......................................................................................................................................... 29
3.2. Study Drug Administration .................................................................................................................... 30
3.3. Clinic Confinement ................................................................................................................................ 31
3.4. Pharm acokinetic Assessments ................................................................................................................ 31
3.4.1. Plasma Pharmacokinetic Collection ..................................................................................... 31
3.5. Safety Assessments ...............................................................
................................................................. 31
3.6. Pharm acody namic Biomarker Assessments ........................................................................................... 31
3.7. Optional Genomic Research ................................................................................................................... 31
3.
8. End of Study ........................................................................................................................................... 32
4. SUBJECT POPULATION .................................................................................................................................. 33
4.1. Number of Subjects and Subject Selection ............................................................................................ 33
4.2. Inclusion Criteria .................................................................................................................................... 33
4.2.1. All Subjects .......................................................................................................................... 33
4.2.2. Subjects with Impaired Hepatic Function ............................................................................ 34
4.2.3. Healthy Matched Control Subjects ....................................................................................... 35
4.3. Exclusion Criteria ................................................................................................................................... 36
4.3.1. All Subjects .......................................................................................................................... 36
4.3.2. Subjects with Impaired Hepatic Function ............................................................................ 37
4.3.3. Healthy Control Subjects ...................................................................................................... 38
5. STUDY DRUGS ................................................................................................................................................. 39
5.1. Enrollment  and Blinding ....................................................................................................................... 39
5.2. Description and Handling of GS -9674 ................................................................................................... 39
5.2.1. Form ulation .......................................................................................................................... 39
5.2.2. Packaging and Labeling ....................................................................................................... 39
5.2.3. Storage and Handling ................................
........................................................................... 40
5.3. Dosage and Administration of Study Drug ............................................................................................ 40
5.4. Fed State Dosing .................................................................................................................................... 40
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 3 23March 20185.5. Meals ...................................................................................................................................................... 40
5.6. Dispensing, Accountability, and Disposal or Return of Study Drug ...................................................... 41
5.7. Concomitant Medications and Other Protocol Restrictions ................................................................... 41
5.7.1. Concomitant Medications ..................................................................................................... 41
5.7.2. Other Protocol Restrictions .................................................................................................. 43
6. STUDY ASSESSMENTS ................................................................................................................................... 44
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 44
6.2. Pretreatment Assessments ...................................................................................................................... 48
6.2.1. Screening Visit ..................................................................................................................... 48
6.2.2. Admission Assessments ....................................................................................................... 48
6.3. Check -in Assessments ............................................................................................................................ 49
6.4. Treatment Assessments .......................................................................................................................... 49
6.5. Posttreatment Assessments .................................................................................................................... 49
6.6. Assessments for Premature Discontinuation from Study ....................................................................... 49
6.7. Criteria for Discontinuation of Study Drug for Multiple Dose Studies .................................................. 49
6.8. Pharm acokinetic Assessments ................................................................................................................ 50
6.8.1. Plasma PK Collection ........................................................................................................... 50
6.9. Pharm acody namic Assessments ...............................................................
.............................................. 50
6.10. Optional Genomic Sample ..................................................................................................................... 51
6.11. Safety Assessments ...............................................................
................................................................. 51
6.11.1. Electrocardiogram Assessment ............................................................................................ 51
6.11.2. Physical Examination ........................................................................................................... 52
6.11.3. Vital Signs ............................................................................................................................ 52
6.11.4. Body  Mass Index ...............................................................
................................................... 52
6.11.5. Clinical Laboratory Tests/Assessments ...............................................................
................. 52
6.11.6. Creatinine Clearance ............................................................................................................ 53
6.11.7. Adverse Events/Concomitant Medications/Protocol Restrictions ........................................ 53
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 54
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious A
dverse Events ................................. 54
7.1.1. Adverse Events ..................................................................................................................... 54
7.1.2. Serious Adverse Events ........................................................................................................ 54
7.2. Assessment of Adverse Events and Serious Adverse Events ...............................................................
..55
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 55
7.2.2. Assessment of Severity ........................................................................................................ 56
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 56
7.3.1. Requirements for collection prior to study drug initiation: .................................................. 56
7.4. Gilead Reporting Requirements ............................................................................................................. 57
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessment
s as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 58
7.6. Toxicity Management ............................................................................................................................ 58
7.7. Study Specific Stopping Criteria ............................................................................................................ 59
7.8. Special Situations Reports ...................................................................................................................... 59
7.8.1. Definitions of Special Situations .......................................................................................... 59
7.8.2. Instructions for Reporting Special Situations ....................................................................... 60
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 62
8.1. Analysis Objectives and Endpoints ........................................................................................................ 62
8.1.1. Analysis Objectives .............................................................................................................. 62
8.1.2. Primary Endpoint ................................................................................................................. 62
8.1.3. Secondary Endpoint ............................................................................................................. 62
8.2. Analysis Conventions ............................................................................................................................. 62
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 4 23March 20188.2.1. Analysis Sets ........................................................................................................................ 62
8.3. Data Handling Conventions ................................................................................................................... 63
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 63
8.5. Interim Analysis ................................................................
..................................................................... 63
8.6. Safety Analysis ....................................................................................................................................... 63
8.6.1. Extent of Exposure ............................................................................................................... 63
8.6.2. Adverse Events ..................................................................................................................... 64
8.6.3. Laboratory Evaluations ........................................................................................................ 64
8.6.4. Other Safety Evaluations ...............................................................
....................................... 64
8.7. Pharm acokinetic Analysis ...................................................................................................................... 64
8.8. Pharm acody namics Analysis .................................................................................................................. 65
8.9. Pharm acokinetics and Pharm acodynamics Analysis .............................................................................. 65
8.10. Sample Size ............................................................................................................................................ 65
9. RESPONSIBILITIES ................................
.......................................................................................................... 66
9.1. Investigator Responsibilities .................................................................................................................. 66
9.1.1. Good Clinical Practice .......................................................................................................... 66
9.1.2. Institutional Review Board/Independent Ethics Committee Revie w and 
Approval ............................................................................................................................... 66
9.1.3. Informed Consent ...............................................................
.................................................. 67
9.1.4. Confidentiality ...................................................................................................................... 67
9.1.5. Study Files and Retention of Records .................................................................................. 67
9.1.6. Case Report Forms ............................................................................................................... 69
9.1.7. Study Drug Accountability and Return ................................................................................ 69
9.1.8. Inspections ............................................................................................................................ 70
9.1.9. Protocol Compliance ............................................................................................................ 70
9.2. Sponsor Responsibilities ........................................................................................................................ 70
9.2.1. Protocol Modifications ......................................................................................................... 70
9.2.2. Study Report and Publications ............................................................................................. 70
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 70
9.3.1. Payment Reporting ............................................................................................................... 70
9.3.2. Access to Information for Monitoring .................................................................................. 70
9.3.3. Access to Information for Auditing or Inspections .............................................................. 71
9.3.4. Study Discontinuation .......................................................................................................... 71
10. REFERENCES ................................................................................................................................................... 72
11. APPENDICES .................................................................................................................................................... 74
Appendix 1. Investigator Signature Page .................................................................................................... 75
Appendix 2. Management of Clinical and Laboratory Adverse Events ...................................................... 76
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 77
Appendix 4. Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities .......... 79
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 5 23March 2018LIST OF IN -TEXT TABLES
Table 1-1. Exposure Margins for GS-9674 Based on Observed GS-9674 Exposure after 
Administration of 300 mgGS-9674 QD under Fasting Conditions at Steady -State in 
Cohort 4 Compared to Exposures Observed at NOAEL doses in Mouse and 
Cynomolgous Monkey ........................................................................................................... 19
Table 1-
2. Preliminary Plasma Pharmacokinetic Parameters of GS-9674 Follow ing Single and 
Multiple Dose Administration of GS-9674 Under Fasting Conditions in Healthy 
Volunteers (GS-US-402-1851). .............................................................................................. 22
Table 1
-3. GS-US-402-3885: Preliminary GS -9674 and GS -716070 PK Parameters Following 
a Single Dose of GS -9674 30 mg in Subjects with Hepatic Impairment or Normal 
Hepatic Function ................................................................
.................................................... 25
Table 5-1. List of Disallowed Medications .............................................................................................. 42
Table 6-1. Schedule of Assessments ........................................................................................................ 45
LIST OF IN -TEXT FIGURES
Figure 3-1. Cohorts 1, 2, and 3 Study Schema .......................................................................................... 30
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 6 23March 2018PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title : A Phase 1 Open -Label, Parallel -Group, Adaptive, Single -Dose Study  
to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674
in Subjects with Normal and I mpaired Hepatic Function
IND Number:
EudraCT Number:127960
Not Applicable
Study Centers 
Planned:Multiple Sites in the United States and New Zealand
Objectives: The primary  objective of this study  is as follows:
To evaluate the single -dose pharmacokinetics of GS - 9674 in 
subjects with impaired hepatic function relative to matched, 
healthy  controls with normal hepatic function
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerabili ty of GS-9674 single dose 
administration in subjects with normal hepatic function, or mild, 
moderate, and severe hepatic impairmen t
To evaluate Farnesoid X Receptor (FXR) activation by  GS- 9674
as measured b y pharmacody namic (PD) markers in subjects with 
normal hepatic function, or mild, moderate and severe hepatic 
impairment
Study Design: Phase 1, open -label, single -dose, parallel -group, staggered -cohort, 
pharmacokinetic (PK) study
Number of Subjects 
Planned:Enroll approximately 60 subjects for 48 evaluable:
Cohort 1: GS -9674: 20 [10 per group (mildly impaired and matched 
controls) for 8 evaluable per group]
Cohort 2: 
GS-9674: 20 [10 per group (moderatel y impaired and 
matched controls) for total 8 evaluable per group]
Cohort 3: 
GS-9674: 20 [10 per g roup (severel y impaired and matched 
controls) for total 8 evaluable per group]
A subject with normal hepatic function may  serve as a matched 
control across cohorts evaluating the same GS-9674 dose. 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 7 23March 2018Target Population: Subjects with hepatic impairment will be enrolled based upon the 
Child -Pugh -Turcotte (CPT) classification s ystem for mild hepatic 
impairment (CPT Class A; Cohort 1) moderate hepatic impairment 
(CPT Class B; Cohort 2) or severe hepatic impairment (CPT Class C; 
Cohort 3). The control group will consist of matched health y subjects 
with normal hepatic function.
Duration of Dosing: 1 day
Study  Duration: Up to 15 Da ys (not including screening window)
Diagnosis and Main 
Eligibility  Criteria:Cohort 1: Male and nonpregnant/nonlactating female subjects aged   
≥ 18 y ears with mildly  impaired and normal hepatic function. Each 
subject in the control group will be matched for age (± 10 y ears), 
gender, race, and bod y mass index (± 15% 18 ≤ BMI  ≤
36 kg/m²) 
with a subject in the mild hepatic impairment group. Subjects with 
mild hepatic impairment must have a score of 5 -6 on the CPT
Classification at Screening without evidence of worsening clinical 
and/or laboratory  signs of hepatic impairment within 2 m onths prior 
or within the screening period.
Cohort 2: Male and nonpregnant/nonlactating female subjects aged ≥ 
18 years with moderatel y impaired and normal hepatic function. Each 
subject in the control group will be matched for age (± 10 y ears), 
gender, ra ce, and bod y mass index (± 15% 18 ≤ BMI  ≤36 kg/m² ) 
with a subject in the moderate hepatic impairment group. Subjects 
with moderate hepatic impairment must have a score of 7 -9 on the 
CPT Classification at Screening without evidence of worsening 
clinical an d/or laboratory signs of hepatic impairment within 2 
months prior or within the screening period.
Cohort 3: Male and nonpregnant/nonlactating female aged ≥ 18 y ears 
with severel y impaired and normal hepatic function. Each subject in 
the control group will be matched for age (± 10 years), gender, race, 
and body  mass index (± 15% 18 ≤ BMI ≤36kg/m² ) with a subject in 
the severe hepatic impairment group. Subjects with severe hepatic 
impairment must have a score of 10 -15 on the CPT Classification at 
Screening w ithout evidence of worsening clinical and/or laboratory  
signs of hepatic impairment within 2 months prior or within the 
screening period.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 8 23March 2018Study  Procedures/
Frequency :Following screening procedures and Day  -2 admission assessments, 
eligible subjects will be enrolled in 1 of three sequential cohorts. 
Subjects will undergo intensive sampling over 24 hours on Day  -1 
after administration of placebo -to-match (PTM) for baseline PD 
markers.  On Day  1 subject s will receive a single dose of 
GS-
967430 mg(3 x 10 mgtablet) orall y for Cohorts 1 and 2 or 10 mg
(1 x 10 mgtablet) for Cohort 3. In general, dosing in subjects with 
normal hepatic function will begin after a matched subject with 
hepatic impairment has completed PK assessments.
Cohorts 1 through 3 will be do
sed in a sequential manner, with dosing 
of subjects in Cohort 2 (moderate hepatic impairment) and Cohort 3 
(severe hepatic impairment) proceeding after review of safety  and 
available preliminary  pharmacokinetic data from hepatic impaired 
subjects in the previous cohorts. Based on the cumulative review of 
safet y and PK data, sequential cohorts may  or may  not be initiated at 
the discretion of the investigator and Sponsor.
Study Visits and Confinement
Following screening assessments, eligible subjects will be admitted to 
the clinic on Day  -2 and confined to the clinic for the duration of the 
study  until discharge on Day  5.
Subjects will be required to return for a Follow -up (FU) visit 10
-14 
days after study  drug dosing.
Study Drug Administration
The study  drug will be supplied as GS-9674 tablets strengths of 
10mgor PTM.  All study  treatments will be administered with 240 
mL of water.
Study  Treatments will be administered in the fed state as described 
below.
Fed state dosing:
Study  drugs will be administered fo llowing an overnight fast (no food 
or drinks except water) for at least 10 hours and within 5 minutes of 
completing a standardized meal (moderate- fat-calorie breakfast 
containing ~600 kcal and 25% to 30% fat will be provided). The meal 
should be initiated 30 minutes prior to study  drug administration. 
Subjects will fast until after collection of the 4 -hour PK/PD sample, 
relative to study  drug dosing.
Additionally , subjects will be restricted from water consumption from 
1 hour before through 2 hours after do sing, except for the water given 
with the study  drugs and the standardized meal.  A standardized meal 
may be provided to subjects after the 4
-hour post -dose PK/PD draw.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 9 23March 2018Pharmacokinetic Assessments
Plasma PK Collection
Intensive PK sampling will occur relat ive to dosing of GS-9674 at the 
following time points for each cohort:
Day 1: -0.5, 0 (pre -dose, ≤ 5 minutes prior to dosing), 0.25, 0.5, 1, 
1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours 
post-dose
Plasma concentrations of GS-9674 (and its metabolites, as applicable) 
will be determined and PK evaluated. Pharmacokinetic parameters 
will be estimated, as appropriate.
In addition, on Day  1 at the 3 and 5 hours post dose time -points, an 
additional plasma samples will be collected for plasma protein 
binding evaluation. Alternatively , pre-dose samples may  be utilized 
for plasma protein binding evaluation.
A blood sample for PK analy sis will also be collected at the Early  
Termination (ET) visit (if applicable) and may  be anal yzed.
Pharmacodynami c (PD) Assessments
Plasma and/or Serum PD Collection
Blood samples will be collected relative to dosing of GS-9674 or 
PTM to measure PD biomarkers including but not limited to FGF19 
(fibroblast growth factor 19) and C4 (7 -alpha -hydroxy -4-cholesten -3-
one) for GS-
9674 at the following time points for each cohort:
Day -1: -0.5, 0 (predose, ≤ 5 minutes prior to dosing), 0.25, 0.5, 1, 
1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 (relative to Day  1 
dosing time assignment)
Day 1: -0.5, 0 (pre -dose, ≤ 5 
minutes prior to dosing), 0.25, 0.5, 1, 
1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours 
post-dose
A single blood sample will be collected for anal ysis including but not 
limited to bile acids at the following time point:
Day 1: -0.5 hours predose
A blood sample for PD analy sis will also be collected at the Early  
Termination (ET) visit (if applicable) and may  be anal yzed.
Genomic Sample
For subjects who provide consent, an additional blood sample will be 
collected for genetic research to identify  or validate genetic markers 
that may  be predictive of the safet y and/or tolerability  of study  drug 
used in this protocol. This sample should be collected on Day 1, but 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 10 23March 2018may be collected at any time during the study  or at a separate post -
study  visit, if necessary .
Safety Assessments --Cohorts 1, 2, and 3
Complete Phy sical exam: Screening and ET visit (if applicable) 
Symptom -directed phy sical exam: Day s -2, 5, and FU visit
Vital signs (blood pressure, pulse, respiration rate, and temperature): 
Screening, Day s -2, 1 (predose and at approximately  3 hours 
postdose), 5, and FU visit or ET visit (if applicable)
Height, Weight, and BMI: Screening
Clinical L aboratory  Tests (hematology , fasting chemistry , and 
urinaly sis: Screening, Day s -2 (two sets of safet y labs will be 
collected upon clinic admission; one will be sent to the central lab and 
another will be sent to the sites’ local lab to obtain results in time for 
enrollment on Day  1) , 5, and FU visit or at ET visit (if applicable)
Coagulation (PT, P TT, INR): Screening and FU Visit
Urine drug/alcohol assessment: Screening, Day  -2, and at the FU visit 
or at ET visit (if applicable).
12-lead ECG: Screening, Day s -2, 5, and at the FU visit or ET visit (if 
applicable)
Serum Pregnancy  Test (female subjects of childbearing potential): 
Screening
Urine Pregnancy  Test (female subjects of childbearing potential): 
Days -
2, 5, and at the FU visit or at ET visit (if applicable)
FSH (female subjects ≤ 54 y ears old with amenorrhea > 12 months): 
Screening
Serology  (Hepatitis B surface antigen (HBVsAg), Hepatitis C 
antibody  (HCV -Ab), Human immunodeficiency  virus (HIV)- 1/2: 
Screening
Assessment of Adverse Events (AEs) and concomitant medications 
will continue throughout the study .
Test Product, Dose, 
and Mode of 
Administration:Cohorts 1 and 2: A single oral dose of GS-9674 30mg(3 x 10 mg
tablet) administered on Day  1
Cohort 3: A single oral dose of GS-9674 10 mg(1 x 10 mgtablet) 
administered on Day 1
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 11 23March 2018Reference Therapy, 
Dose, and Mode of 
Administration:Cohor ts 1 and 2: A single oral dose of PTM GS-9674 30mg(3 x 
PTM 10 mgtablet) administered on Day  -1 
Cohort 3: A single oral dose of PTM GS-9674 10 mg(1 x PTM 
10mgtablet) administered on Day  -1
Criteria for 
Evaluation:
Safety : Safety  will be evaluated by physical examinations, vital signs, clinical 
laboratory  tests and ECGs at various time points during the study , and 
by documentation of adverse events (AEs)
Efficacy : Not applicable .
Pharmacokinetics: The following plasma PK parameters will be calcula ted for GS-9674, 
as applicable: % AUC exp, AUC last, AUC inf, Cmax, Tmax, Clast, T last, z, 
CL/F, V/F and T ½.
Percent plasma protein binding will be determined and PK parameters 
adjusted for protein binding will be estimated.
Pharmacod ynamics: FXR activation will be evaluated b y PD markers including but not 
limited to FGF19 and C4.
Statistical Methods: GS-
9674 plasma concentrations and PK parameters will be listed and 
summarized by  hepatic function group within each cohort (normal 
and mildly  impaired, modera tely impaired, or severel y impaired) 
using descriptive statistics (e.g., sample size, arithmetic mean, 
geometric mean, % coefficient of variation [%CV], standard
deviation [SD], median, minimum, and maximum). An anal ysis of 
variance (ANOVA) appropriate for a parallel design with hepatic 
function group as a fixed effect will be fit to the natural logarithmic 
transformation of PK parameters (AUC last, AUC inf, and C max) for 
GS-9674. The 90% confidence intervals (CIs) will be constructed for
the geometric least 
squares mean (GLSM) ratio of PK parameters for 
GS-9674 in the mild, moderate, or severe hepatic impairment group 
versus the control (normal hepatic function) group.
Safety  data will be listed by  subject and summarized by  hepatic 
function group and frequenc y of event/abnormality or descriptive 
statistical summaries, as appropriate.
Pharmacod ynamic and PK/PD relationships will be explored as 
appropriate.
For each cohort, with 16 (8 per group) evaluable subjects, the 
estimated upper limit of one- sided 95% CI of the GL SM ratio of 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 12 23March 2018(mild, moderate or severe) hepatic impaired group vs control (normal 
hepatic function), with regards to AUC last, AUC inf, and C max, would
be less than 200% with ≥ 88% probability , if the estimated GL SM 
ratio were 1.0. This is assuming a SD of no more than 0.463 on a 
natural logarithm scale, supported b y previous Gilead stud y 
GS-US-402- 1851. With 25% overage, a total sample size of
60
subjects (10 per group, 20 per cohort) will be required.
This study  will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) including archiving of essential documents.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 13 23March 2018GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
%CV %coefficient ofvariation
AE adverse event
AME absorption, metabolism, and elimination
ALT alanine aminotransferase (previously serum glutamic pyruvic transaminase
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC inf area under the concentration versus time curve extrapolated to infinite time, calculated as 
AUC last+ (C last/λz)
AUC last area under the concentration versus time curve from time zero to the last quantifiable
concentration
AUC tau area under the concentration versus time curve over the dosing interval
BID twice a day
BLQ below  limit of quantitation
BMI body mass index
bpm beats per minute
BUN blood urea nitrogen
C4 7-alpha -hydroxy -4-cholesten -3-one
CBC complete blood count
CBER Center for Biologics Evaluation and Research
CDER Center for Drug Evaluation and Research
CFR Code of Federal Regulations
CI confidence interval
CK creatine kinase
CL systemic clearance
CL/F apparent oral clearance after administration of the drug:
CL/F = Dose/AUC inf, where “Dose” is the dose of the drug
CLss/F apparent oral clearance at steady state after administration of the drug:
CLss/F = Dose/AUC tau, where “Dose” is the dose of the drug
Clast last observed quantifiable concentration of the drug
CL cr creatinine clearance
Cmax maximum observed concentration of drug
CPK creatine phosphokinase
CRF case report form
CRO contract (or clinical) research organization 
CSR clinical study report
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 14 23March 2018CTA clinical trial application
Ctau observed drug concentration at the end of the dosing interval
DDI drug-drug interaction
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
EudraCT European Clinical Trials Database
eGFR estimated glomerular filtration rate
ESA erythropoiesis -stimulating agent
eSAE electronic serious adverse event
ET early termination
EU European Union
E2 depressed estradiol
FDA Food and Drug Administration
FGF19 fibroblast growth factor 19
FSH follicle -stimulating h ormone
FU follow -up
FXR Farnesoid X Receptor
GCP Good Clinical Practice
GCSF Granulocyte colony stimulating factor
Gilead Gilead Sciences, Inc.
GLSM geometric least -square smean
HBV hepatitis B virus
HBsAb hepatitis B surface antibody
HBSAg hepatitis B surface antigen
HCC hepatocellular carcinoma
HCV hepatitis C virus
HDL high-density lipoprotein
HDPE high-density polyethylene
HIV, HIV-1 human immunodeficiency virus, type 1
HLGT high-level group term
HLT high-level term
IB investigator’s brochure
ICF informed consent form
ICH International Conference on Harmonization (of Technical Requirements for Registration
of Pharmaceuticals for Human Use)
ID identification
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 15 23March 2018IEC independent ethics committee
IND investigational new drug (application)
IRB institutional review board
IUD intrauterine device
LDL low-density lipoprotein
LLT lower-level term
LLOQ lower limit of quantitation
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
MM medical monitor
NDA new drug application
PD pharmacodynamic(s)
PG pharmacogenomics
PI principal investigator , package insert
PK pharmacokinetic(s)
PRinterval electrocardiographic interval occurring betw een the onset of the P w ave and the QRS 
complex representing time for atrial and ventricular depolarization, respectively
PT preferred term , prothrombin time
PTT partial thromboplastin time
QA quality assurance
QRS electrocardiographic deflection betw een the beginning of the Q w ave and termination of 
the S wave, representing time for ventricular depolarization
QT electrocardiographic interval betw een the beginning of th e Q w ave and termination of the 
T wave, representing the time for both ventricular depolarization and repolarization to 
occur
QTcF QT interval corrected for heart rate using the Fridericia formulation
RBC red blood cell
SADR serious adverse drug reaction
SAE serious adverse event 
SAP statistical analysis plan
SD standard deviation
SOC system organ class
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
Tlast time (observed time point) of C last
Tmax the time (observed time point) of C max
TOST two one -sided t ests
TQT thorough QT
TT thrombin time
t1/2 estimate of the terminal elimination half -life of the drug, calculated by dividing the natural 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 16 23March 2018log of 2 by the terminal elimination rate constant (λ z)
ULN upper limit of normal
US, USA United States, United States of America
Vz/F apparent volume of distribution of the drug
WBC white blood cell
WHO World Health Organization
%AUCexp percentage of AUC extrapolated betw een AUClast and AUCinf
λz elimination phase of the log serum/plasma/PBMC concentration versus time curve of the 
drug
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 17 23March 20181. INTRODUCTION
1.1. Background
Chronic liver disease and the consequences of end- stage liver disease are increasing globall y 
despite improved prevention and treatment of viral hepatitis. This is due to the emerging 
epidemics of obesit y, metabolic syndrome, and diabetes mellitus that are leading to an increased 
incidence of nonalcoholic fatt y liver disease (NAFLD). Nonalcoholic fatty liver disease is 
characterized b y the excess accumulation of lipid droplets within the liver, also known as hepatic 
steatosis. Prevalence rates of NAFLD rang e from 6% to 37% worldwide {Vernon et al 2011},
{Ong et al 2007}. Nonalcoholic steatohepatit is (NASH), an aggressive form of NAFLD 
characterized b y the presence of inflammation and hepatocellular ballooning, with or without 
fibrosis, is present in approximately  25% of patients with NAFLD. Nonalcoholic steatohepatitis 
is associated with increased liver-related mortalit y {Williams et al 2011}, { Ong et al 2007 }. In 
the United States (US), it has been estimated that 3% to 6% of the popula tion {Vernon et al 
2011}, {Wanless et al 1990 }, or the equivalent of up to 15 million adults, have NASH.NASH 
represents a significant and growing unmet medical need for which there are no currentl y 
approved therapies. Furthermore, as NASH is a manifestation of the metabolic sy ndrome, risk 
factors for cardiovascula r disease (eg, atherosclerotic disease, car diac arrh ythmogenicit y) 
frequentl y coexist in these patients {Faramawi et al 2008 }, {Voulgari et al 2010 }, {Dietrich et al 
2014}. A treatment that targets the underly ing metabolic disorder could potentially  ameliorate 
these cardiovascular risks and associated morbidity  and mortality .
Nonalcoholic steatohepatitis is primarily  thought to occur as the result of the metabolic 
syndrome, the impact of obesity , insulin resistance, and dy slipidemia in the liver. Simple 
steatosis is not sufficient to cause liver injury ; it is the presence of inflammation and 
hepatocellular injury  on the background of steatosis that defines NASH and results in th e 
progression to end
-stage liver disease and its complications. The “2 -hit” hypothesis of NASH 
suggests that in the setting of steatosis and metabolic dy sfunction, increased oxidative stress and 
the generation of reactive oxy gen species (ROS) likely  mediate the inflammatory  changes in the 
liver (steatohepatitis) that may  lead to progressive fibrosis {Dowman et al 2010}, {Kannel et al 
1982}, {Koek et al 2011 }, {Sumida et al 2013} . The major pathway s in NASH disease 
progression include those involved in metabolic dysfunction in the hepatocyte, and activation of 
hepatic stellate cells and macrophages leading to progressive inflammation and liver fibrosis. 
Advanced fibrosis and cirrhosis are characterized by  extensive collagen deposition a nd 
remodeling of the extracellular matrix.
Over time, NASH may  result in progressive liver fibrosis, ultimately  leading to cirrhosis in
10-20% of affected patients. Advanced fibrosis (bridging fibrosis or cirrhosis) is associated with 
increased morbidity  and mortality  {Ekstedt et al 2015}, {Yeh et al 2014 }. Patients with cirrhosis 
may develop hepatocellular carcinoma (HCC) and other complications of end -stage liver disease, 
including jaundice, fluid retention (edema and ascites), portal hy pertension and v ariceal
bleeding, impaired coagulation and hepatic encephalopathy . Decompensated liver disease, as 
defined b y the development of one of the above complications, has a high mortality  and the onl y
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 18 23March 2018known effective treatment is liver transplantation. With the increasing prevalence of obesit y and 
obesity -related diseases, NASH is expected to become the leading indication for liver 
transplantation, and the leading etiology  of HCC among liver transplant recipients in the US 
{Wong et al 2014 }, {Afzali et al 2012}.
1.2. GS-
9674
GS-9674 is a potent agonist of Farnesoid X Receptor (FXR) whose activity  in intestinal 
epithelial cells results in the release of fibroblast growth factor 19 (FGF19). FGF19 is an 
endocrine peptide which drives a signaling cascade to decrease lipogenesis, gluconeogenesis, 
hepatic trigly ceride accumulation, and bile acid synthesis. Please refer to the Investigator’ s 
Brochure (IB) for additional information on GS-9674 including:
In Vitro FXR agonism
Nonclinical Pharmacokinetics and In Vitro Metabolism
Nonclinical Pharmacology and Toxicology
1.2.1.1. General Information
For further information on GS-9674, refer to the current IB for GS- 9674
1.2.2. Preclinical Pharmacology , Pharmacokinetics and Toxicology
The nonclinical toxicity  profile of 
GS-9674 has been assessed in mice and cy nomolgus monkey s 
administered GS-9674 orally  for up to 4 weeks. GS-9674-related effe cts were limited to non-
adverse findings in the liver for both species that are likel y related to the pharmacology of the 
compound. In both mice and cy nomolgus monkeys, mild increases in AL P activity , liver weight, 
and hepatocellular h ypertrophy were obser ved. Minimal oval cell hy perplasia was also observed 
in the liver of cy nomolgus monkey s. Additional findings in mice included mild decreases in 
cholesterol and trigl ycerides. Findings were observed at ≥ 100 mg/kg/day  in mice and 
300mg/kg/day  in cy nomolgus monkey s. Because these findings were considered
non-adverse, 
the no observed adverse effect levels (NOAELs) in mice and cy nomolgus monkey s were the 
highest doses evaluated (600 and 300 mg/kg/day , respectivel y).
Preliminary  steady -
state PK data from Cohort 4 (administration of GS-9674 300 mg) in the 
ongoing First -in-Human study  of GS-9674 (GS-SU-402- 1851: Section 1.2.5 ) indicate adequate 
safet y margins based on GS-
9674 exposures at the nonclinical NOAEL doses in mouse and 
cynomolgus monkey  (Table 1-1).
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 19 23March 2018Table 1-1. Exposure Margins for GS-9674 Based on Observed GS-9674 Exposure 
after Administration of 300 mgGS-9674 QD under Fasting 
Conditions at Steady -State in Cohort 4 Compared to Exposures 
Observed at NOAEL doses in Mouse and Cynomolgous Monkey
SpeciesNOAEL
Exposur eMargi naDose mg/kg/dayAUC tau
µg•h/mL
Mouse 600 189 15
Cynomolgus Monkey 300 148 12
a Calculated using observed AUC tauof 12.5 μg•h/mL from Healthy Volunteers administered 300 mgGS-9674 QD
1.2.3. Nonclinical Pharmacology
GS-9674 is a potent and selective agonist of FXR. This conclusion is supported by  the following 
data: 1) modeling demonstrated an interaction of GS-9674 with the binding domain of FXR 
consistent with agonist activity , 2) GS-9674 i nduced an agonist response in a time -resolved 
fluorescence resonance energy  transfer (TR -FRET) biochemical assay  with an EC50 of 16 nM, 
which was comparable to that of other known FXR agonists, and 3) GS-9674 did not activate the 
structurally  similar bile acid receptor TGR5, did not activate other nuclear hormone receptors, 
and did not bind to a panel of other off -target receptorsN and enzy mes.
The cellular potency  of GS-9674 to activate FXR -mediated transcription was characterized using 
a firefl y luciferas e reporter gene engineered under the control of a FXR/RXR response element 
(PC-402- 2012). GS-9674 caused complete FXR activation with an EC50 value of 43 nM, which 
was more potent than chenodeox ycholic acid (EC50 of 1770 nM).
Oral dose -ranging experiments in male cy nomolgus monkey s demonstrated maximal increases in 
plasma FGF19 at a dose of 5 mg/kg (PC -402- 2016). In addition, the oral administration of
GS-
9674 (30mg/kg) to cy nomolgus monkey s directly  activated intestinal FXR, as measured b y 
the expression of FXR -target genes in the ileum (15- fold increase in FGF19 mRNA, and a 2 -fold 
increase in organic solute transporter (OST)α and OSTβ mRNA) (PC -402- 2005).
The effects of GS-
9674 on FGF19 levels were compared in cy nomolgus monkey s following both 
oral and in travenous (IV) administration (PC -402- 2016). Despite greater exposures following IV 
administration, only  the oral administration of 
GS-9674 increased circulating FGF19 levels. 
These data indicate that intestinal FXR agonism by GS-9674 causes FGF19 producti on, whereas 
low sy stemic free drug concentrations limit effects following IV administration of GS - 9674.
GS-
9674 was evaluated in a choline -deficient high fat diet /NaNO2 rat model of liver fibrosis 
(PC-402- 2015). This in vivo model utilized “2 hits” to mim ic the metabolic and oxidative stress 
components of NASH disease in humans {Nakamoto et al 2009 }, {Murakami et al 2013 }. 
Treatment with GS-9674 dose-dependently  reduced both biochemical and histological measures 
of liver fibrosis in this model.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 20 23March 2018Safety  pharmacology  studies have been conducted to examine the potential effects of GS - 9674
on the cardiovascular (CV) , respiratory , and central nervous s ystem (CNS) sy stems. There were 
no GS - 9674- related effects on the CNS or respiratory  system in mice administered up to
600mg/kg. In addition, there was no significant human ether
-a-go-go-related gene inhibition at 
conce ntrations up to 100 μM or GS-9674- related effects on the CV s ystem in monkey s 
administered up to 300 mg/kg.
Overall, the results from these pharmacology  studies demonstrate that GS-9674 is a potent and 
selective agonist of intestinal FXR with the potential to benefit NASH patients by  inducing 
FGF19 production.
1.2.4.
Nonclinical Pharmacokinetics
GS-9674 is expected to be poorly  absorbed in humans based on low oral bioavailability  in 
nonclinical species (approximately  10% and 20% when dosed as  
). Low, pH -dependent solubility  and efflux transport have been 
identified as factors likely limiting GS-9674 absorption.
The low sy stemic clearance (CL) of GS-9674 in rats, dogs and monkey s was considerabl y low er 
than the predicted hepatic clearance based on in vitro studies with hepatocytes. This discrepancy 
is most likely  a result of protein-restricted clearance in vivo due to the very high plasma protein 
binding (> 99.6%) across species. The volume of distribution (V ss) of GS-9674 was consistent 
with extracellular fluid (ranging from 0.16 -0.21 L/kg) in rats, dogs, and monkey s.
Using the estimates of bioavailability , CL, and Vss in nonclinical species, and assuming linear 
kinetics, a 300 -mg twice -daily  dose of GS -9674 is projected to give a C maxof 3.8 μg/mL and 
AUC 0-24of 34.4 μg/mL •h in humans.
After oral dosing to albino and pigmented mice, [14C] GS-9674- derived radioactivity  was 
distributed to most of the tissues, with the highest maximum concentrations of ra dioactivity  
determined in organs of absorption and excretion. Generally  similar distribution patterns and 
tissue concentrations of [14C] GS-
9674- derived radioactivity  were observed in albino and 
pigmented mice with no observed binding to melanin. I n both st rains, no quantifiable 
radioactivity  was detected in brain, suggesting [14C] GS-
9674- derived radioactivity  did not cross 
the blood:brain barrier. Fecal elimination was a predominant route of elimination of
[14C] GS-
9674- derived radioactivity  in both mice (85 .7% and 5.45% recovered in feces and 
urine, respectivel y) and monkeys (78.2% and 69.7% recovered in feces in intact and bile duct 
cannulated animals) likely representing drug not absorbed from the gastrointestinal tract. 
Approximately  6% of the administere d radioactivity  was excreted in bile and urine in monkey s. 
Radiolabeled material was primarily excreted within the first 48 hours.
GS-9674 undergoes oxidative metabolism in human hepatocy tes. Comparison of metabolism in 
hepatocy tes from mice, rats, dogs, monkey s, and humans did not identify  any metabolites unique 
to humans, supporting the selection of mice and monkeys for the assessment of t he toxicology  of 
GS-9674. Of the recombinant human CYP isozy mes tested, CYP2C8, CYP3A4, and CYP2C19 
were shown to metabolize GS - 9674. Potent inhibitors of these CYPs therefore may  affect 
CCI
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 21 23March 2018metabolism of GS - 9674. GS - 9674 had little inhibitory  effect on the ac tivities of CYP1A2, 
CYP2B6, CYP2C19 or CYP2D6 (I C50 > 25 μM). For CYP2C8, CYP2C9, and CYP3A, I C50 
values of 2.4 to 13.6 μM were obtained but GS-9674 was not a mechanism -based inhibitor of 
these enzy mes. GS-9674 showed moderate inhibition of human UGT1A1, s odium -taurocholate 
cotransporting poly peptide (NTCP), and bile salt export pump (I C50 2.8 -7.7 μM). GS-9674
inhibited human OATP1B1, OATP1B3, and OATP2B1 with I C50 values of 0.68, 0.41, and 0.21 
μM, respectivel y. GS-9674 therefore has the potential to affect hepatic/intestinal uptake of 
OATP substrates or metabolism of CYP2C8, CYP2C9, or CYP3A4 substrates when its 
concentrations are sufficiently  high. However, low solubility , high protein binding (> 99.98%) 
and low sy stem ic levels reduce the potential for GS-9674 to cause drug -drug interactions via 
inhibition of metabolic enzy mes and transporters.
GS-9674 was a substrate for efflux transporters P- glycoprotein and breast cancer resistance 
protein, as well as the uptake tran sporters OATP1B1, 1B3, and 2B1, and NTCP. I nhibitors or 
genetic pol ymorphisms affecting the activity  of these transporters may  affect GS-9674 intestinal 
absorption and hepatic uptake. This was illustrated in an in vivo study  in monkey s where 
pretreatment w ith cy closporin A, a known inhibitor of efflux transporters, increased the 
bioavailability  of GS-9674 approximately  5-fold.
GS-
9674 is highly  selective for FXR over other nuclear hormone receptors in cell -based reporter 
assay s, including those associated w ith potential for induction of human drug metabolizing 
enzy mes and transporters (eg, pregnane X receptor, constitutive androstane receptor). Thus the 
liability  of GS-9674 to cause drug -drug interactions through proteins regulated by  these nuclear 
receptors is low.
1.2.5. Clinical Trials of GS-9674
Ongoing clinical experience with GS-9674 includes a Phase 1 clinical study (GS-US-402- 1851). 
A brief PK summary of results from this ongoi n
gstudyis presented below.
1.2.5.1. GS-US-402-1851
Study  GS-US-
402-1851 is an ongoing Pha se 1, randomized, single -blind, placebo -controlled, 
single -and multiple -dose study  in health y volunteers with 4 pre -specified staggered dose -
escalation cohorts and 4 adaptive randomized, single
-blind, placebo -controlled, single- and 
multiple dose cohorts with adaptive dose selection and dose frequency .
Approximately  60 subjects have been enrolled into the 4 pre -specified cohorts with preliminary  
data presented below.
Summary  of subjects enrolled/dosed and safet y data available for Cohorts 1 -4 based on inte rim 
safet y data from 13- April -2016:
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 22 23March 2018Preliminary  safet y data for GS -9674 after single and multiple dose administration of 10, 30, 100, 
or 300 mgGS-9674 demonstrated no adverse events of grade 3 or higher, no serious adverse 
events, and no subjects disconti nued GS-9674 due to adverse event. Overall rate of an y adverse 
event was  4/15 (27%) in the 10mg cohort, 4/15 (27%) in the 30mg cohort, 3/15 (20%) in the 
100mg cohort, and 4/15 (27%) in the 300mg cohort. All adverse events were grade 1 or 2 in 
severit y, did not result in dose interruption or discontinuation and were not felt to be related to 
GS-9674 by the investigator.
Preliminary  PK parameters for GS-9674 after single and multiple dose administration of 10, 30, 
100 or 300 mgGS-9674 under fasting conditio ns in healthy  volunteers  are presented below in 
Table 1-2. GS - 9674 was absorbed quickl y with the maximum plasma concentration (C max) 
occurring between 1.25 to 3.25 hours post dose (m edian T max) with a bi -phasic decline after C max.  
Across the doses tested, GS-9674 exhibited a median half- life (T 1/2) of 5.56 to 12.8 hours. The 
lower observed median half- life 5- 6 hours in the 10 mgand 30 mgcohorts may  be a result of 
plasma concentrations falling below the limit of quantitation dur ing the distributional phase of 
the profile. In general, GS-9674 AUC and C maxincreased less than dose proportionally  above 
10mgupon single and multiple dosing.  As expected based on the short GS-9674 T 1/2and once 
daily  dosing, minimal to no accumulation was observed for GS-9674 AUC, C maxor C 24from 
single to multiple dose administration.
Table 1-2. Preliminary Plasma Pharmacokinetic Parameters of GS-9674
Following Single and Multiple Dose Administration of GS-9674 Under
Fasting Conditions in Healthy Volunteers (GS-US-
402-1851).
Param eter 
(N=12) Mean 
(%CV)Cohort 1: 10 mg
(N=12)Cohort 2: 30 mg
(N=12)Cohort 3: 100 mg
(N=12)Cohort 4: 300 mg
(N=12)
Single 
DoseAUC inf (ng*hr/ml) 1260 (30.3) 2480 (37.2) 7740 (93.9) 12,500 (33.9)
Cmax (ng/ml) 304 (41.6) 580 (48.9) 2590 (118) 3060 (66.2)
C24(ng/ml) 2.61 (49.9)b6.04 (35.7) 23.5 (40.0) 76.0 (67.4)
Tmax(hr)a3.00 (2.38, 4.00) 3.00 (2.38, 3.63) 1.75 (1.38, 2.63) 1.25 (1.00, 3.13)
T1/2 (hr)a5.56 (5.46, 6.41) 8.10 (5.74, 9.58) 11.2 (8.30, 11.9) 12.4 (11.4, 13.9)
Mulitple 
DoseAUC tau (ng*hr/ml) 1280 (35.8) 2890 (23.5) 6720 (59.2) 8490 (48.8)
Cmax (ng/ml) 322 (42.4) 718 (32.8) 2230 (75.9) 2330 (81.5)
Ctau (ng/ml) 2.75 (55.5) 7.90 (50.3) 36.3 (42.5) 70.1 (56.3)
Tmax(hr)a2.50 (1.50, 3.50) 3.00 (1.88, 3.13) 1.50 (1.00, 2.63) 3.25 (1.00, 5.00)
T1/2 (hr)a6.75 (5.64, 8.45) 5.95 (5.54, 6.55) 8.99 (6.84, 11.49) 12.8 (10.0, 14.7)
Pharmacokinetic parameters are presented as Mean (%CV), and shown to 3 significant digits 
a T maxand T 1/2 are presented as median (Q1; Q3) 
b N=11
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 23 23March 20181.2.5.2. GS-US-402- 3885 (current study )
Study  GS-US-
402-3885 is an ongoing Phase 1, open -label, parallel - group, singl e dose stud y 
evaluating the safet y, tolerability, PK, and PD of GS-9674 in subjects with normal hepatic 
function and mild, moderate, or severe hepatic impairment. Up to 60 subjects are planned for 
enrollment in 1 of 3 hepatic impairment cohorts: Cohort 1 (mild hepatic impairment, CP T Class
A), Cohort 2 (moderate hepatic impairment, CP T Class B), and Cohort 3 (severe hepatic 
impairment, CPT Class C).
Within each cohort, each subject with impaired hepatic function (N=10 per cohort) will be 
matched for age (± 10 years), sex, race, and bod y mass index (BMI : ± 15%) with a control 
subject with normal hepatic function (N=10 per cohort). Data from health y subjects may  be used 
in >1 cohort if a subject was an appropriate match for a subject with hepatic function in >1 
cohort. All subjects will receive a single oral dose of GS-9674 30 mgin the fed state on Day  1 
with PD collected on Day -1 and Day  1.
1.2.5.2.1. Subject Di sposition 
As of 1 November 2017, a total of 37 subjects were enrolled and 36 subjects had completed 
study  treatment. One subject prematurely  discontinued study  treatment due to quality  issues at 
the site that justified a suspension in dosing at the site. No subjects prematurely  discontinued due 
to an AE, withdrew consent, or were lost to follow -
up.
1.2.5.2.2. Preliminary  Safet y Results 
Overall, 8.8% of subjects had a treatment-emergent adverse event (TEAE) of Grade 1 or 2. There 
was 1 SAE of gastrointestinal bleed t hat was not related to study  drug. This subject had a history  
of esophageal variceal bleeding and experienced bleeding requiring hospitalization and blood 
transfusion. There were no pregnancies or deaths. 
In the mild hepatic impairment cohort, there were 2 subjects (20%) that had Grade 3 lab 
abnormalities of elevated GGT and low platelets. The Grade 3 GGT was stable from the 
subject’s baseline. There was 1 health y matched control subject (10%) who had Grade 3 lab 
abnormalities in total cholesterol and LDL cholesterol, which were stable from their baseline. In 
the moderate hepatic impairment cohort, 2 subjects (20%) had Grade 3 lab abnormalities. One 
subject had low ly mphocy tes, and the other subject had elevated total bilirubin and low platelets. 
The platel et count was not changed from the subject’s baseline. One subject, who had a SAE of 
gastrointestinal bleeding in the moderate hepatic impairment cohort (described above), had a 
Grade 4 lab abnormalit y of low hemoglobin.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 24 23March 20181.2.5.3. Preliminary  PK Results
Preliminary  PK results are presented below and in Table 1-3:
Cohort 1 (mild hepatic impairment; CP T Class A): GS-
9674 exposure (AUC infand C max) was 
higher in subjects with mild hepatic impairment (approximately  76% and 57%, respectively ) 
as compared to subjects with n ormal hepatic function. I n subjects with mild hepatic 
impairment, exposure (AUC infand C max) of the metabolite GS -716070 was similarly  higher 
(approximately  64% and 25%, respectively ). Both anal ytes had minor changes in plasma 
protein binding (unbound frac tion [fu] increased ~30%). GS-9674 is a substrate of hepatic 
OATP and CYP2C8 expression/activity  of these transporters and enzy mes may be altered in 
patients with 
hepatic impairment and may contribute to the observed higher sy stemic 
exposure of GS -9674. At a dose of 30 mgQD in subjects with mild hepatic impairment, 
exposure margins relative to preclinical NOAEL exposures for both parent and metabolite 
are expected to remain adequate.
Cohort 2 (moderate hepatic impairment; CP T Class B): GS-
9674 exposure (AU Cinfand C max) 
was higher in subjects with moderate hepatic impairment (approximately  2.3-and 1.6- fold, 
respectivel y) as compared to subjects with normal hepatic function. Exposure (AUC inf) of the 
metabolite GS -716070 was also higher (approximately 1.6 -fold) with minimal change in 
Cmax. Plasma unbound fraction (fu) of GS-9674 and GS -716070 was  increased ~96% and 
~85%, respectively, in moderate hepatic impairment, leading to a > 4 -fold and > 3 -fold 
increase in free drug exposures of parent and metabolite, respectively .
Preliminary  PD results for Cohort 1 are also available for change from baseline (Day  1) in 
plasma FGF19 and serum 7 -alpha -hydroxy-4-cholesten - 3 -one (C4) levels following a single 
30mgdose of GS-9674. Changes in FGF19 and C4 following a sing le dose of GS-9674 were 
similar in the mild hepatic impairment subjects as compared to the health y matched controls as 
indicated b y the PD parameter ratios (mild hepatic impairment/health y) for C maxand AUC 2-12hr 
for FGF19 (1.1 and 1.1, respectivel y) and f or C minand AUC 2-12hr for C4 (0.82 and 0.87, 
respectivel y) in thatthe ratios were not significantly  different from 1.
Based on the preliminary PK and PD data from this study  as well as the overall safet y profile of 
GS-9674, dose adjustments are not considered necessary  in subjects with mild hepatic 
impairment.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 25 23March 2018Table 1-3. GS-US- 402-3885: Preliminary GS- 9674 and GS -716070 PK 
Parameters Following a Single Dose of GS-9674 30 mgin Subjects 
with Hepatic Impairment or Normal Hepatic Function
Cohort AnalyteMean (%CV) PK 
Param eterMatched Healthy 
Control (N=10)Hepatic 
Impairment 
(N=10)%GMR
(90% CI)
1GS-9674AUC inf(hr ng/mL) 3030 (40.5) 5410 (40.2) 176 (127, 253)
AUC last(hr ng/mL) 2970 (41.4) 5380 (40.4) 178 (128, 247)
Cmax(ng/mL) 604 (45.6) 994 (53.7) 157 (108, 229)
GS-716070AUC inf(hr ng/mL) 1440 (49.7) 2330 (44.8) 164 (104, 259)
AUC last(hr ng/mL) 1400 (51.1) 2300 (44.8) 169 (115, 247)
Cmax(ng/mL) 179 (42.6) 234 (50.8) 125 (85.0, 188)
2GS-9674AUC inf(hr ng/mL) 2810 (30.3) 8280 (91.4) 230  (163, 324)
AUC last(hr ng/mL) 2460 (30.9) 8220 (91.1) 249  (169, 367)
Cmax(ng/mL) 496 (40.2) 909 (52.5) 164  (115, 233)
GS-716070AUC inf(hr ng/mL) 1380 (47.7) 3160 (81.8) 163  (95.1, 280)
AUC last(hr ng/mL) 1340 (48.8) 3090 (80.9) 197  (117, 329)
Cmax(ng/mL) 168 (51.6) 181 (61.5) 89.5 (54.3, 147)
Data reported to 3 significant figures
1.3. Rationale for T his Study
Hepatic disease may  alter absorption, disposition and elimination of drugs resulting in PK and 
subsequently  PD changes. As such, the objective of this study  is to investigate potential clinicall y 
relevant differences in the pharmacokinetics and safet y of a dministration of the single dose of 
GS-9674 to subjects with mild (Class A), moderate (Class B) or severe (Class C) hepatic 
impairment as determined by  Child -Pugh -Turcotte (CPT) classification {Pugh et al 1973}, 
compared to matched subjects with normal hepatic function with the goal to provide dosing 
recommendations to subjects with hepatic impairment. Administration of GS-
9674 as a single -
dose is expected to accurately  predict PK under steady -state conditions a nd is thus deemed 
satisfactory  for an evaluation in this study .
This study  design is consistent with recommendations as outlined in the FDA Guidance for 
Industry  entitled “Pharmacokinetics in Patients with I mpaired Hepatic Function: Study  Design, 
Data Anal ysis, and Impact on Dosing and Labeling” { U.S. Department of Health and Human 
Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 
Center for Biologics Evaluation and Research (CBER) 2003 }. All subjects in the impairm ent 
group will have clinically  manifested, confirmed, primary  liver disease (and not hepatic 
impairment due to some other cause). Evaluation of pharmacokinetics and safet y of GS-
9674 in 
moderate or severe liver impairment will commence after the review of safety  and available PK 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 26 23March 2018data from subjects with mild, or moderate hepatic impairment respectively .   The trial will also 
enroll health y controls, matched for bod y mass index, age, and sex.
1.3.1. Rationale for the Dose Selection
This study  will evaluate the impact of hepatic impairment on the single dose PK of 30 mg
(Cohorts 1 and 2) and 10 mg(Cohort 3) GS -9674 administered under fed conditions (moderate 
fat breakfast based on results from food effect evaluations in study  GS-US-402-1851) . These 
doses were selecte
d based on the observed PK of single -and mul tiple-dose administration of 
GS-9674 up to 300 mgin study  GS-US- 402- 1851 in healthy  subjects and on the preliminary  data 
from Cohorts 1 and 2 of this study , which show edincreased unbound exposure with degree o f 
hepatic impairment.  Based on the PK of GS-
9674 across the range of doses evaluated, and 
GS-9674 exposure and PD response observed in study  GS-US- 402- 1851, alterations of GS- 9674
PK observed in this study  as a result of hepatic impairment are expected to reflect the magnitude 
of alteration of stead y-state GS-9674 pharmacokinetics in subjects with NASH.
Short -term safet y data from clinical study GS-US-402- 1851 and GS-US-402-2102  indicate that 
GS-9674 exposures higher than those expected in this study  are well tolerated in health y subjects
with no clinically  significant or treatment limiting adverse events or laboratory  abnormalities.
This study  will proceed in three sequential cohorts starting with mi ld (CPT Class A), then 
moderate (CPT Class B), followed b y severe (CPT Class C) hepatic impairment with evaluation 
of preliminary  safet y and PK data from hepatic impaired subjects from each cohort prior to 
initiation of subsequent cohorts. I n addition, the proposed 30 mgdose of GS -9674 in Cohorts 1 
and 2 is 10- fold lower than the highest dose level previously  evaluated (300 mg) in study  
GS-US-402-1851 which provided GS- 9674 exposures 12- to 15 -fold lower than those observed 
at the NOAEL in the 4 -week repe at dose toxicity  studies in the mouse and cy nomolgous monkey  
(Section 1.2.21.2.2).   Based on the preliminary  exposures observed in Cohort 1 and 2 
(Section 1.2.5.2) and expected further increases in unbound exposure in Cohort 3, the do se of 
GS-
9674 is being reduced to 10 mgin subjects with severe hepatic impairment to cautiously
maintain adequate exposure margins.
With the proposed doses, it is unlikely  that plasma exposures of GS-9674 in hepatic impairment 
subjects would exceed previously  observed exposur es in health y volunteers or exceed exposures 
observed at the NOAEL in the toxicity  studies.
1.4. Risk/Benefit Assessment for the Study
Potential risks of a participant’s study  involvement include unknown AEs, general risks 
associated with frequent clinic visit s and laboratory blood draws, and the associated pain and 
discomfort of phlebotomy. Strategies to mitigate these risks include close monitoring of lab 
values as well as AEs. Parameters for discontinuation of the study  drug due to AEs will be well ‑
defined and closel y followed.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 27 23March 2018There is no direct benefit to subjects participating in this study ; however, data from this study  
will support the development of GS-9674 for the treatment of NASH.  Potential benefits may  
include the participant’s contribution to und erstanding the safet y and tolerability  of a single -dose 
of GS-9674, how much GS- 9674 gets into the blood stream, and how these may  differ in those 
with hepatic insufficiency .
Considering the above, the benefit -risk balance for this study  is considered positive.
1.5. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 28 23March 20182. OBJECTIVES
The primary objective sof this study  areas follows:
To evaluate the single -
dose pharmacokinetics of GS - 9674 in subjects with impaired hepatic 
function relative to matched, healthy controls with normal hepatic function
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerabili ty of GS-9674 single dose administration in subjects with 
normal hepatic function, or mild, moderate, and severe hepatic impairment
To evaluate FXR activation by  GS- 9674 as measured b y PD markers in subjects with normal 
hepatic function, or mild, moderate and severe hepatic impairment
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 29 23March 20183. STUDY  DESIGN
3.1. Study Design
This protocol describes a Phase 1, open- label, adaptive, single -dose, parallel -group, staggered -
cohort, PK study  to evaluate the single -dose pharmacokinetics of GS - 9674 in subjects with 
normal and im paired hepatic function. Up to approximately  60 subjects will be enrolled.
Cohort 1: GS-9674: 20 [10 per group (mildly  impaired and matched controls) for 8 evaluable 
per group]
Cohort 2: 
GS-9674: 20 [10 per group (moderatel y impaired an d matched controls) for total 
8evaluable per group]
Cohort 3: GS-
9674: 20 [10 per group (severel y impaired an d matched controls) for total 
8evaluable per group]
Eligible subjects include male and nonpregnant/nonlactating female subjects, aged  ≥ 18 y ears 
with mildly , modera tely impaired, severel y impaired, and normal hepatic function will be 
enrolled into the study . Each subject in the control group will be matched for age (± 10 years), 
gender, race and bod y mass index (± 15% 18 
≤BMI  ≤36 kg/m² ) to a subject in the hepatic 
impairment group. A subject with normal hepatic function in a cohort may  serve as a match to a 
subject with hepatic impairment in another cohort.
Cohorts 1 through 3 will be dosed in a sequential manner, with dosing of subjects in Cohort 2 
(moderate hepati c impairment) and Cohort 3 (severe hepatic impairment) proceeding after 
review of safet y and available preliminary  pharmacokinetic data from hepatic impaired subjects 
in the previous cohorts. Based on the cumulative review of safet y and PK data, sequential
cohorts may  or may  not be initiated at the discretion of the investigator and Sponsor.
In general, dosing in subjects with normal hepatic function will begin after a matched subject 
with hepatic impairment has completed PK assessments. The study desi
gn ispresented in
Figure 3-1.
GS-9674
Protocol GS-US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 30 23March 2018Figure 3-1. Cohorts 1, 2, and 3 S tudy Schema
3.2. Study Drug Administration
The study  drug will be supplied as GS-9674 tablets or placebo to match, in strengths of 10 mg. 
All study  treatments will be administered with 240 mL  of water.
Study  Treatments will be administered in the fed state as described below.
Fed state dosing:
Study  drugs will be administered following an overnight fast (no food or drinks except water, for 
at least 10 hours) and within 5 minutes of completing a standardized meal (moderate -fat-calorie 
breakfast containing ~600 kcal and 25% to 30% fat will be provided). The meal should be 
initiated 30 minutes prior to study  drug administration. Subjects wi ll l fast until after collection 
of the 4- hour PK/PD sample, relative to study  drug dosing.
Additionally , subjects will be restricted from water consumption from 1 hour before through
2 hours after dosing, except for the water given with the study drugs and the standardi zed meal. 
A standardized meal may be provided to subjects after the 4 -hour post -dose PK/PD draw.
Please refer to Section 5.3for additional information for study
drug dosage and administration.

GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 31 23March 20183.3. Clinic Confinement
Eligible subjects will be confined beginnin g on Day  -2 until the completion of assessments on 
Day 5. Subjects will be required to return for a Follow- up visit 10- 14 day s after study  drug 
dosing.
3.4. Pharmacokinetic Assessments
PKassessments will occur on assigned study  days as outlined in Table 6-1.
3.4.1.
Plasma Pharmacokinetic Collection
Plasma concentrations of GS-9674 (its major metabolites, as applicable) will be determined and 
PK evaluated. PK parameters will be estimated as appropriate.
3.5. Safety Assessments
Safety  assessments will be performed through the study  as outlined in Table 6-1.
3.6.
Pharmacodynamic Biomarker Assessments
PD assessments will be performed throughout the study  as outlined in Table 6-1and in 
Section 6.9.
3.7. Optional Genomic Research
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 32 23March 2018 
 
 
 
 
 
3.8. End of Study
The end of this study  will be the last subject’s last observation (or visit).
CCI
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 33 23March 20184. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Sel ection
A total of up to approximately  60 unique subjects will be enrolled in the study . Eligible subjects 
include male and nonpregnant/nonlactating female subjects at least 18 years of age with mildly  
impaired, moderately  impaired, severel y impaired, and n ormal hepatic function. I f necessary , 
replacement subjects may be enrolled if subjects do not complete all intensive PK procedures 
with Sponsor approval. Replacement subjects will not be enrolled for subjects who discontinue 
the study  due to treatment -related adverse events.
Classification of hepatic impairment will be assigned as follows:
Mild: Class A, CPT score 5-6
Moderate: Class B, CPT score of 7-9
Severe: Class C, CPT score of 10 -15
Based on CPT classification, subjects with hepatic impairment and healthy  matched controls will 
be enrolled as described in Section 5.1. The control group will consist of matched healthy  
subjects with normal hepatic function. Each subject in the hepatic impairment group will be 
matched for age (± 10 years), gender, and BMI (± 15%, 18 
≤ BMI ≤ 36 kg/m ²) with a subject in 
the health y control group.
4.2.
Inclusion Criteria
4.2.1. All Subjects
Subjects must meet all of the following inclusion criteria to be eligible for par ticipation in this 
study .
1.Have the ability  to understand and sign a written informed consent form (ICF), which must 
be obtained prior to initiation of study  procedures.
2. Must be ≥ 18 y ears of age, inclusive at Screening.
3.Must be able to comply  with the smoking restrictions at the study  site.
4.Have a calculated bod y mass index (BMI) from 18 to 36 kg/m² , inclusive, at study  Screening.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 34 23March 20185.Have a creatinine clearance (CL cr)80 mL /min (using the Cockcroft -Gault method 
{Cockcroft et al 1976 } ) based on serum creatinine and actual bod y weight as measured at
Screening
Male: (140–age iny e ars)(wtinkg)CrCl (mL/min)
72 (serum creatinine 
inmg/dL)
Female : (140–ageinyears)(wtinkg)0.85  CrCl (mL /min)
72 (serum creatinine 
inmg/dL)
6.Females of childbearing potential (as defined in Appendix 3) must have a negative serum 
pregnancy test at Screening and 
negative urine pregnancy atDay -2 unless permanent ly 
sterile or greater than two years post- menopausal
7.Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified highlyeffective method(s) of contraception 
as described in Appendix 3.
8.Male subjects must refrain from sperm donation from clinic admission, throughout the study  
period, and continuing for at least 90 days following the last dose of study drug.
9.Subjects have not donated blood within 56 da y
s ofstudyentryor plasma within 7 days of 
studyentry and must refrain from blood donation from clinic admission, throughout the stud y 
period, and continuing for at least 30 days following the las t dose of study drug.
10.Have either a normal 1 2-lead electrocardiogram (ECG) or one with abno rmalities that are 
considered clinically insignificant bythe investigato r
.
11.Must be willing and able to comply with all study requirements.
4.2.2. Subjects with Impaired He patic Function
Subjects with mild, moderate, or severe hepatic impairment must also meet the following 
additional inclusion criteria to be eligible for participation in this study :
12.Aside from hepatic insufficiency , the subject must, in the opinion of the investigator, be 
sufficiently  healthy  for study  participation based upon medical history , physical examination, 
vital signs, and screening laboratory  evaluations
13.Must have diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically  
significant changes within 3 months (90 day s) prior to study  drug administration (Day  -1)
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 35 23March 201814.Must meet all of the following laboratory  parameters at Screening:
ALT value ≤ 10 × ULN
AST value ≤ 10 × ULN
Absolute neutrophil count ≥ 1,000/mm3
Platelets ≥ 25,000/mm3
Hemoglobin ≥ 8 g/dL
α-fetoprotein ≤ 50 ng/mL
15.Subjects with severe hepatic impairment must have a score on the Child Pugh Turcotte scale 
of 10 -15 at Screening. If a subject’s score changes during the course of the study , the score at 
Screening will be used for classification.
16.Subjects with moderate hepatic impairment must have a score on the Child Pugh Turcotte 
scale of 7- 9 at Screening. If a subject’s score changes during the course of the study , the 
score at Screening will be used for classification.
17.Subje cts with mild hepatic impairment must have a score on the Child Pugh Turcotte scale of 
5-6 at Screening. If a subject’s score changes during the course of the study, the score at 
Screening will be used for classification
18.Subjects with hepatic impairment with comorbid diseases not associated with hepatic 
impairment requiring medication(s) must be taking the medication(s) without a change in 
dose for at least 4 weeks (or 5 half -lives, whichever is longer) prior to Screening. Any  change 
in the dosage during this timeframe should be reviewed and approved by  the Sponsor.
4.2.3.
Healthy Matched Control Subjects
Health y matched control subjects must also meet the following additional inclusion criteria to be 
eligible for participation in this study :
19.Must, in the opinion of the Investigator, be in good health based upon medical history, 
physical examination, vital signs, and screening laboratory evaluations.
20.Must meet all of the following laboratory  parameters at Screening:
INR ≤ 1 × ULN
Albumin ≥ 1 × LLN
Total bilirubin ≤ 1 × ULN
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 36 23March 2018AST value ≤ 1 × ULN
ALT value ≤ 1 × ULN
Alkaline phosphatase ≤ 1 × ULN
α-fetoprotein ≤ 1 × ULN
21.Must match in age (± 10 y ears), gender, race, and BMI (± 15% of ≥ 18 and ≤ 36) with the 
respective subject in hepatic impairment group.
4.3. Exclusion Criteria
4.3.1. All Subjects
Subjects who meet an y of the following exclusion criteria will not be enrolled in this study .
1.Pregnant or lactating subjects.
2.Have received an y investigational compound within 30 days prior to study  dosing (Day  -1).
3.Current alcohol or substance abuse judged by  the investigator to potentiall y interfere with 
subject compliance or subject safet y.
4.A positive test result for human immunodeficiency  virus (HIV -1/2) antibody
5.Have poor venous access that limits phlebotomy .
6.Have been treated wit
h systemic steroids, immunosuppressant therapies, or chemotherapeutic 
agents within 3 months prior to Screening or expected to receive these agents during the 
study  (eg, corticosteroids, immunoglobulins, and other immune -or cy tokine -based 
therapies).
7.Significant serious skin disease, such as but not limited to rash, food allergy , eczema, 
psoriasis, or uticaria.
8.Significant drug sensitivity  or drug allergy  (such as anaphy laxis or hepatoxicity ).
9.Known hy persensitivity  to the study  drugs their metabolites or to formulation excipients (see 
Section 5.2.1 ).
10.Significant cardiac disease including history  of m yocardial infarction based on ECG and/or 
clinical history , any  history  of ventricular tachy cardia, congestive heart failure, or dilated 
cardiom yopath y with lef t ventricular ejection fraction < 40%, implanted defibrillator or 
pacemaker), a famil y history of Long QT S yndrome, or unexplained death in an otherwise 
healthy  individual between the ages of 1 and 30 years.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 37 23March 201811.Syncope, palpitations, or unexplained dizziness.
12. Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid 
hypersecretory  conditions.
13.Medical or surgical treatment that permanentl y alters intestinal absorption (eg, gastric or 
intestinal surgery ).  A history  of cholecy stectomy  is not exclusionary .
14.Are unable to comply  with study  requirements or are otherwise believed, b y the study  
investigator, to be inappropriate for stud y participation for an y reason.
4.3.2. Subjects with Impaired Hepatic Function
Subjects with mild, moderate, or severe hepatic impairment meeting any  of the following 
additional exclusion criteria are not to be enrolled in this study :
15.Aside from hepatic insufficiency , serious or active medical or ps ychiatric illness that, in the 
opinion of the I nvestigator, would in terfere with subject treatment, assessment, or 
compliance with the protocol. This would include renal, cardiac, hematological, unstable 
hepatic, pulmonary  (including chronic asthma), endocrine (eg, diabetes), central nervous, 
gastrointestinal (including an ulcer), vascular, metabolic (thy roid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, or malignancy  that are clinically  significant or 
requiring treatment.   
16. Chronic hepatitis B virus (HBV) infection, defined as a positive test f or hepatitis B surface 
antigen (HBsAg), unless the patient has been treated with a nucleos(t)ide analog (eg, 
tenofovir or entecavir) for at least 6 months and the HBV DNA b y pol ymerase chain reaction 
(PCR) assay  has been persistently  undetectable for at le ast 6 months.
17.Positive test for drugs of abuse, including alcohol at Screening or on Day  -2/check -in, with 
the exception of opioids and tetrah ydrocannabinol (THC, marijuana) under prescription and 
Investigator verification for pain management. Subjects who screen positive for 
benzodiazepines may  be allowed if prescribed under the care of a ph ysician and after review 
by Investigator and Sponsor.
18.Requires paracentesis > 1 time per month.
19.Subjects with hepatic impairment with co -morbid diseases not associated with hepatic 
impairment requiring medication(s) must be taking the medication(s) without a change in 
dose for > 3 months prior to Screening.
20. Changes in concomitant medications or dosage used to treat s ymptoms of hepatic impairment 
or associated co- morbid c onditions that could lead to clinically  significant changes in 
medical conditions during the course of the study  that would affect the ability  to interpret 
potential drug -drug interactions within 28 day s prior to dosing.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 38 23March 2018All concomitant medications includi ng over -the-counter and herbal products must be approved 
by the Investigator and Medical Monitor prior to study  enrollment and study  drug administration.
21.Prior placement of a portosy stemic shunt (such as TI PS), unless vascular imaging indicates 
the shunt has no current blood flow.
4.3.3. Healthy Control Subjects
Health y matched controlled subjects meeting an y of the following additional exclusion criteria 
are not to be enrolled in this study :
22.A positive test result for HCV antibody  or HBVsAg.
23. Positive test for dru gs of abuse, including alcohol at Screening or on Day  -2/check -in.
24.Have an y serious or active medical or ps ychiatric illness (including depression) which, in the 
opinion of the I nvestigator, would interfere with subject treatment, assessment, or 
compliance with the protocol. This would include renal, cardiac, hematological, hepatic, 
pulmonary  (including chronic asthma), endocrine (including diabetes), central nervous, 
gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, or malignancy  that are clinically  significant or 
requiring treatment.
25.History  of liver disease.
26.Have taken an y prescription medications or over -the-counter medications including herbal 
products within 28 days of commencing study drug dosing (Day  -1) with the exception of 
vitamins, acetaminophen, ibuprofen, and hormonal contraceptive medications.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 39 23March 20185. STUDY  DRUGS
5.1. Enrollment  and Blinding
It is the responsibility ofthe Investigator to ensure that the subject is eligible for the stud yprior 
to enrollment. Subjects will be assigned a S creening number at the time of consent.
At Screening, stu dy participants will be assigned to a cohort within their respective part.  Once 
eligibility has been confirmed, eligible subjects will be assigned a subject number starting on 
Day1 and will receive the study treatments as described in Section 5.3.
All Screening and Day
-2 tests and procedures must be completed prior to the administration of 
the first dose of stu dydrug on s tarting on Day -1. Once a subject number has been assigned to a 
subject, it will not be reassigned to another subject. Ifnecessary , replacement subjects may be 
enrolled after discussion and approval from Sponsor. A new unique subject number will be 
assigned to the repla cement subject.
A subject number list will be provided to the study center bytheSponsor.
5.2. Description and Handling o f GS-9674
5.2.1. Formulation
GS-9674 is supplied as 10 mgstrength (as free form equivalent) tablets. The tablets contain 
 
 
 GS-9674 tablets 10 mg, are round, plain- faced, film -coated, orange tablets.
Placebo
-to-match (PTM) GS-9674 tablets are identical in size, shape, color and appearance to 
their corresponding strength of active GS-9674 t ablets. Placebo- to-match GS-9674 tablets 
contain the following inactive ingredients: 
 
5.2.2. Packaging and Labeling
GS-9674 tablets, 10 mg, and PTM GS-9674 are packaged in white, high -density  polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets, a silica gel de siccant, and poly ester packing 
material. Each bottle is enclosed with a white, continuous thread, child -resistant screw cap with 
an induction -sealed, aluminum- faced liner.
Study  drugs to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
CCI
CCI
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 40 23March 2018(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations.
5.2.3. Storage and Handling
GS-9674 tablets and PTM GS-9674 tablets should be stored at controlled room temperature until 
required for administration. Controlled room temperature is defined as 25ºC (77ºF); excursions 
are permitted between 15ºC and 30ºC (59ºF and 86ºF).  Storage conditio ns are specified on the 
label.
Until study  drug tablets are dispensed to the subjects, all bottles of study  drugs should be stored 
in a securely  locked area, accessible only  to authorized site personnel. To ensure the stability  and 
proper identification, t he drug products should not be stored in a container other than the 
container in which they  were supplied. Consideration should be given to handling, preparation, 
and disposal through measures that minimize drug contact with the bod y. Appropriate 
precautions should be followed to avoid direct ey e contact or exposure through inhalation when 
handling GS-9674 tablets.
5.3. Dosage and Administration of Study Drug
The study  drugs will be supplied as GS-9674 tablets, in strengths of 10 mgand PTM GS - 9674. 
All study  treatments will be administered with 240 mL  of water. Study  treatments will be 
administered in the fed state.
5.4. Fed State Dosing
Study  drugs will be administered following an overnight fast (no food or drinks except water, for 
at least 10 hours). Study  drugs w ill be administered within 5 minutes of completing a 
standardized meal (moderate -fat
-calorie breakfast containing ~600 kcal and 25% to 30% fat will 
be provided). The meal should be initiated 30 minutes prior to study  drug administration. 
Subjects will fast until after collection of the 4 -hour PK/PD sample, relative to study  drug 
dosing.
Additionally , subjects will be restricted from water consumption from 1 hour before through 2 
hours after dosing, except for the water given with the study  drugs and the sta ndardized meal. A 
standardized meal may  be provided to subjects after the 4- hour post -dose PK/PD draw.
5.5. Meals
All meals and/or snacks given to subjects during their stay  in the clinical study  facility  will be 
standardized for all subjects and should be similar in calorie and fat content and taken at 
approximately  the same time each day .  All meals provided must be approved by  the Sponsor. 
Components of meals (eg, margarine, jelly , bread) should be given to subjects in individual 
portions (eg, 1 tablespoo n) per the approved meal schedule. The provision of meal components 
in bulk (eg, a jar of jelly  for subjects to share) should not be practiced. All meals should be given 
at approximately  the same time each day  (eg, 07:30, 12:00, and 18:00).
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 41 23March 20185.6. Dispensing , Acc ountability, and Disposal or Return ofStudy Drug
The Investigator (or designee, eg, stud y center pharmacist) will acknowledge receipt of the stud y 
drug (after reviewing the shipment’s content and condition) from Gilead (or designee). The 
Investigator will maintain an accurate inventory  of all study  drug(s). Each dose of the study  
drug(s) administered at the study  center will be administered by  qualified study  center staff. The 
dose of study  drug(s) administered to subjects in the clinic under the supervisi on of staff will be 
accuratel y recorded on the Study Drug Accountability  Form provided by  Gilead (or on 
equivalent documentation maintained by  the study  center), which indicates the date and quantit y 
of each dosage formulation dispensed to individual subje cts.
Gilead recommends that used and unused study drug supplies, including empty  containers, be 
returned to the shipping facility  from which it came or Gilead Sciences for destruction following 
drug accountability  and drug inventory  reconciliation.
If retu rning drug supplies to the shipping facility  from which it came or to Gilead Sciences is not 
possible, the monitor will evaluate the site’s SOP for study  drug disposal/destruction in order to 
ensure that it complies with Gilead’s requirements. At the end o f the stud y, following final drug 
inventory  reconciliation by  the monitor, the study site will dispose of and/or destroy  all unused 
study  drug supplies, including empt y containers, according to these procedures.
5.7. Concomitant Medications and Other Protocol R estrictions
5.7.1. Concomitant Medications
5.7.1.1. Hepatic Impairment Group 
Concomitant use of certain medications or herbal/natural supplements with study  drug may  result 
in PK and/or PD interactions resulting in increases or decreases in exposure of study  drug or 
these medications.
Concomitant medications taken within 30 day s of Screening through the follow -up visit need to 
be recorded in the source documents and electronic Case Report Forms (eCRFs).
Subjects with hepatic impairment with co -morbid diseases requiring me dication(s) must be 
taking the medication(s) without a change in dose within 28 day s of Day  1.  All concomitant 
medications including over -the-counter and herbal products must be approved by  the 
Investigator and Medical Monitor prior to study  enrollment an d study  drug administration.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 42 23March 2018The following medications are prohibited from 28 days prior to Day -1 through discharge:
Hematologic stimulating agents (e.g. ery thropoiesis- stimulating agents (ESAs); granulocy te 
colony  stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
Chronic sy stemic immunosuppressants including, but not limited to, corticosteroids 
(prednisone equivalent of > 10 mg/day for > 2 weeks), azathioprine, or monoclonal 
antibodies (e.g., infliximab)
Investigational agents or devi ces for any indication
Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducers 
of drug transporters P -gp, BCRP, or OATP, or the drug metabolizing enzyme CYP3A) with 
study  drug(s) may  result in PK interactions resulting in increases or decreases in exposure of 
study  drug(s) or concomitant medications. Examples of representative medications which are 
prohibited from 28 day s prior to Day  -1 through discharge are listed below in Table 5-1:
Table 5-1. List of Disallowed Medications
Drug Class Agents Disallowed
Antibiotics Azithromycin, Clarithromycin, Erythromycin
Acid Reducing Agents Proto n-PumpInhibitors, H2-Receptor Antagonists, Antacid sa
Anticonvulsant sbPhenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine
Antifungals Itraconazole, Ketoconazole
Antimycobacterial sbRifamycins, Isoniazid
Cardiac Medications Amiodarone, Digoxin, Dronedarone, Felodipine, Verapamil, 
Quinidine, Ranolazine, Bosentan, Olmesartan, Telmisartan, 
Valsartan
Herbal/Natural Supplement sbSt.John’s Wort, Echinaccea. Milk thistle (i.e.silymarin), Chinese 
herb sho-saiko-to(orXiao -Shai-Hu- Tang)
HMG -CoA Reductase Inhibitor scfluvastatin, lovastatin, pitavastatin , pravastatin, rosuvastatin
Selective Serotonin Reuptake Inhibitors Fluvoxamine
Other Modafinil
a Pr oton pump inhibitors can be taken up to 7 days before study drug dosing (Day 1).  H2 receptor antagonists can be taken up 
to 3 days before study drug dosing (Day 1). Antacids that directly neutralize stomach pH (i.e. Tums, Maalox) are permitted 
but may not be taken within 4 hours (before or after) study drug administration.
b May result in a decrease in the concentrations of study drugs.
c Use with study drug may resul t in an increase in the concentration of the HMG-CoA Reductase Inhibitors. The 28 day 
washout period does not apply to HMG-CoA Reductase inhibitors, which can be taken up to the day before Day -1.
Medications for disease conditions excluded from the protoc ol (e.g., HIV- 1 infection, active 
cancer, transplantation) are not listed under this Concomitant Medication section and are 
disallowed in the study .
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 43 23March 20185.7.1.2. Subjects with Normal Hepatic Function
The following medications are excluded while subjects with normal hep atic function are 
participating in the stud y:
Any prescription medications or over -the-counter medications including herbal products 
within 28 day s of commencing study drug dosing (Day  -1) with the exception of vitamins, 
acetaminophen, ibuprofen and/or hor monal contraceptives. However, the short term use of 
topical hy drocortisone cream or A&D ointment to treat minor skin irritation due to ECG
leads will be allowed. If a subject requires use of a disallowed medication, a request for such 
use must be reviewed by the Sponsor and if approved, subjects may  continue to participate in 
the study .
Any and all illegal or illicit drug use, including use of prescription drugs outside the care of 
the prescribing ph ysician.
5.7.2. Other Protocol Restrictions
Subjects 
will be required to refrain from the consumption of food and beverages containing 
alcohol products 72 hours prior to the first dose of study  drug and during the course of the 
study  through the follow- up visit.
Subjects will be required to refrain from the use of nico tine or nicotine- containing products 
90 day s prior to first dose of study  drug and during the course of the study  through the 
follow -up visit. 
Subjects will be required torefrain from consumption of grapefruit juice, grapefruits, and 
Seville orange juice 72 hours prior to the first dose of study  drug and during the course of the 
study  through the follow- up visit.
While confined at the study  center, tea, coffee, chocolate, and other foods and beverages 
containing caffeine and other methy l xanthines will be prohibited on each dosing day . Atall 
other times, caffeine -containing beverages and foodstuffs may  be served or withheld in 
accordance with normal study  center practice. Caffeine -containing beverages and foodstuffs 
will not be restricted while subjects are outside of the clinic.
Subjects will be encouraged to avoid strenuous or prolonged exercise, as well as saunas, 
steambaths, and sunbathing or oth er prolonged ultraviolet exposure, eg, in a tanning salon, 
from the 
screening evaluation until completion of the follow -up visit, as these activities are 
known to affect certain clinical laboratory test parameters, (eg,creatine kinase ) and will 
provide false indicators of a pote ntially  treatment -related toxicity . 
Upon every admission to the clinic, each subject will be questioned as to their compliance with 
the above protocol restrictions. If a subject is unable to comply with an y of the restrictions 
described above, the subject’s continued participation in the study  will be reevaluated by  the 
investigator in consultation with the s ponsor.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 44 23March 20186. STUDY  ASSESSMENTS
The study  procedures to be conduct ed for each subject enrolled in the study  are detailed below .
Any deviation from protocol procedures should be noted in the subject’s clinical chart and 
appropriate electronic case report f orms ( eCRFs ). In addition, the sponsor should be promptly  
notified of an y protocol deviations. 
The study  center will not initiate dosing until the following have all been met :
The institutional review board (IRB)/ ethics committee ( EC)/other applicable regulatory  
agencies have reviewed and approved the study  and the informed consent document
.
All requested regulatory  documents have been submitted to and approved by  Gilead .
A master services agreement and/or study 
agreement is executed.
The study  initiation meeting has been cond ucted by the Gilead (or designee).
The initiation meeting will include but is not limited to a review of the protocol, the IB, study  
drugs, and investigator responsibilities.
Documentation of the personally  signed and dated ICFforeach subject, using the study -specific ,
IRB/EC -
approved ICF, is required before initiating the screening process. 
6.1. Subject Enrollment and Treatment Assignment
Entry  into screening does not guarantee enrollment into the study . In order to manage the total 
trial enrollment, Gilead, at its sole discretion, may suspend screening and/or enrollment at an y 
site or trial -wide at any  time .
It is the responsibility  of the investigator to ensure that subjects are eligible to participate in the 
study  prior to enrollment and continue to remain eligible throughout the study .
Once the ICFhas been obtained, all screening and admission tests and assessments have been 
assessed, and stud y eligibility  has been confirmed, subjects will be enrolled to receive stud y drug 
on Day  1.
Subjects will receive the study  treatments as described in Section 5.3.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 45 23March 2018Table 6-1. Schedule of Assessments
Study Procedure ScreenaDay
-2 Day -1 Day 1 Day 4 Day 5bDay 10- 14
FUPeriod ETd
Written Informed Consent X
Medical History X
Com plete Physical Exam X X
Symptom -Driven Physical 
Examinatione X
Height X
Weight X
BMI X
Vital SignsfX X X X X X
HIV-1, HBV, and HCV 
Testingh X
Hem atologyg, hX X X X X
Serum ChemistryhX X X X X
Coagulation X
Α-fetoprotein X
Urinalysis X X X X X
Serum Pregnancy TestiX X
Urine Pregnancy TestiX X X X
FSHjX
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 46 23March 2018Study Procedure ScreenaDay -2 Day -1 Day 1 Day 4 Day 5bDay 10- 14
FUPeriod ETd
Urine Drug and Alcohol 
Screenh X X X X
12-Lead ECG X X X X X
Enrollment X
Placebo Administration X
GS-9674 Administration X
PKAssessmentskX
PD AssessmentslX X X
Genetic SamplemX
Revie w Study Restrictions X X X X X
Clinic Confinement X  ------------------------------ --------------- --------------------------- X
Revie w AEs & 
Concomitant Medicationsn X X  ------------------------------------------------------------------------ X X X
a. Prospective subjects should be screened no more than 28 days prior to administration of the first dose of study drugs.
b. Subjects will be discharged from the clinic on Day 5 following all morning assessments.
c. Subjects will be required to return for a Follow -up visit 10 -14 days after study drug dosing. 
d. Assessments will be performed within 72 hours of early termination from the study.
e. Symptom -driven PEs will be performed on Day 1 (predose), 4, and at the Follow -up Visit
f. Vital signs include blood pressure, pulse rate, respiration rate, and body temperature. To be performed on Day -2, 1 (predose and at approximately 3 hours postdose), 5, and at 
the Follow -up Visit.
g. Hematology: CBC with differentials
h. Fasting serum chemistry: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect bilirubin, GGT, total protein, albumin, bicarbonate, BUN, calcium, chloride, 
creatinine, glucose, phosphorus, magnesium, potassium, sodium, ur ic acid, total cholesterol, HDL, LDL, triglycerides, and amylase (reflex lipase testing is performed in 
subjects with total amylase > 1.5 x ULN).
i. Female subjects of child -bearing potential.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 47 23March 2018j. Female subjects ≤ 54 years old with amenorrhea > 12 months as outlined in Appendix 3kIntensive PK sampling will occur relative to the dosing at the following timepoints:
k. Day 1: -0.5, 0 (pre -dose, ≤ 5 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 9 6 hours post -dose
In addition, on Day 1 at the 3 and 5 hours post dose timepoints, an additional plasma sample will be collected for plasma pro tein binding evaluation. Alternatively, pre -dose 
samples may be utilized for plasma protein binding evaluation
l. Blood samples will be collected relative to dosing of GS-9674 to measure PD biomarkers for FGF19 and C4 GS-9674 at the following timepoints for each cohort: Day -1: -
0.5, 0 (pre -dose, ≤ 5 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 , 6, 8, 10, 12, and 16 (relative to Day 1 dosing time assignment)
Day 1: -0.5, 0 (pre -dose, ≤ 5 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post -dose
A single blood sample will be collected on Day 1, -0.5 hours predose for the determination including but not limited to individual bile acids.
m. For subjects who provide consent, an additional blood sample will be obtained. This sample should be collected on Day 1, but may be collected at any time during the study 
or at a separate post -study visit, if necessary.
n. From the time of obtaining informed consent through the first administration of study drug, record all SAEs, as well as any n on-serious adverse events related to protocol-
mandated procedur
es on the AE eCRF
All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical his tory are to be captured on the medical history CRF. 
See Section 7Adverse Events and Toxicity Management for additional details.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Scienc es, Inc. Amendment 2
CONFIDENTIAL Page 48 19 March 20186.2. Pretreatment Assessments
6.2.1. Screening Visit
Prospective subjects should be screened no more than 28 days prior to administration of the first 
dose of study  drug . If asubject does not begin the treatment phase within this 28 -day window, all 
screening evaluation procedures must be repeated. Screening laboratory  assessment s may  be 
repeated once within 28 days prior to administration of study  drug to rule out laboratory  error.
A sufficient number of subjects will be screened to identify  planned number of subjects for
enrollment .
Subjects should be instructed to fast (no food or drink, except water ), startin g from midnight 
(
00:00) or earlier, as appropriate, on the evening prior to the s creening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Written informed consent must be obtained from each subject b efore initiation of anyscreening 
procedure. After a subject has provided informed consent, the i nvestigator and other study  
personnel will determine if the subject is eligible for participation in the study. This assessment 
will include a review of the in clusion/exclusion criteria and completion of all screening 
procedures as outlined in Table 6-1and described in the following text. 
Eligible subjects meeting all of the inclusion criteria and none of the exclusion criteria will be 
instructed on all protoc ol requirements
,including the restrictions on concomitant medication 
usage and other substances as well as consumption of food or beverages containing alcohol, 
caffeine, or xanthine. Subjects will be asked to arrive at the stud y center on Day  -2for admis sion 
assessments.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adver se events case report form (AE eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical histor y eCRF. See 
Section 7Adverse Events and Toxicity  Management for additional details.
6.2.2. Admission Assessments
6.2.2.1. Admission
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the screening visit to ensu re an 
approximate 8-hour fast prior to the fasted blood sample collection.
Subjects meeting all eligibility  criteria following the screening evaluation will return to the clinic 
for admission assessments on Day  -2. The admission evaluations and/or procedures are outlined 
inTable 6-1.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 49 23March 2018Prior to dosing on Day -1, the results of the clinical and laboratory evaluations (as described in 
Table 6-1must be reviewed by  the i nvestigator to confirm the continued eligibility  of each 
subject to participate in the study . At the time of enrollment subjects will be assigned a 
sequential subject number as described i n
Section 5.1.Subjects will remain confined to the study  
clinic for the duration as described in 
Section 6.2.2.2 and Table 6-1.
Prior to study  drug 
administration, re cord an y SAEs and all AEs related to protocol- mandated 
procedures. After drug administration, report all AEs and SAEs.
6.2.2.2. Clinic Confinement
Subjects will be confined to the study  clinic starting on Day  -2 until completion of assessments 
on Day  5.
6.3. Check -in Assessments
Following completion of screening and Day  
-1 assessments, eligible subjects will be assigned a 
subject number and receive study  treatments as shown in 
Section 5.3. 
6.4. Treatment Assessments
Study  procedures and assessments are outl ined in Table 6-1.
6.5. Posttreatment Assessments
Subjects will be required to return for a Follow -up visit 10 -14 day s after study  drug dosing.
6.6. Assessments for Premature Discontinuation from Study
If the subject discontinues from the study , the 
ET evaluations and/or procedures outlined in 
Table 6-1should be performed within 72 hours of permanentl y discontinuing the stud y.
6.7.
Criteria for Discontinuation of Study Drug for Multiple Dose Studies
Study  treatment may be discontinued in the following insta nces:
Intercurrent illness that would, in the judgment of the 
investigator, affect assessments of 
clinical status to a significant degree
Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or
toxicity  that, in the judgme nt of the i nvestigator, compromises the ability  to continue study -
specific procedures or is considered not to be in the subject ’s best interest
Subject request to discontinue for an y reason
Subject noncompliance
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 50 23March 2018Pregnancy  during the study (refer to Appendi x 4)
Investigator discretion
Discontinuation of the study  at the request of Gilead ,regulatory  agency ,or an IRB/EC
6.8. Pharmacokinetic 
Assessments
6.8.1. Plasma PKCollection
Plasma concentrations of GS-9674 (and its metabolites, as applicable) will be determined and PK 
evaluated. PK parameters will be estimated, as appropriate.
Intensive PK sampling will occur relative to the morning dose of GS-9674 at the following time 
points:
Day 1: -0.5, 0 (pre -dose, ≤ 5minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 
8, 10, 12, 16, 24, 48, 72, and 96 hours post -dose
In addition, on Day  1 at the 3 and 5 hours post dose time -points, an additional plasma samples 
will be collected for plasma protein binding evaluation. Alternativel y, pre -dose samples may  be 
utilized for plasma protein binding evaluation.
A blood sample for PK analy sis will also be collected at the Early  Termination (ET) visit (if 
applicable) and may  be analy zed.
6.9.
Pharmacodynamic Assessme nts 
Blood samples will be collected relative to dosing of GS-9674 to measure PD biomarkers 
including but not limited to FGF19 and C4 for GS-9674 at the following time points for each 
cohort:
Day-1: -0.5, 0 (pr e - dose,≤ 5 minutes prior to dosin g), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5,
5, 6, 8, 10, 12, and 16 (relative to Day 1 dosing time assignment)
Day1: -0.5, 0 (pr edose, ≤ 5 minutes prior to dosin g), 0.25, 0.5, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,
10, 12, 16, 24, 48, 72, and 96 hours post- dose
Foranalysis including but not limited to individual bile acids a single blood sample will be 
collected at the following time point for each cohort:
Day1: -0.5 hours predose
A blood sample for PD analysis will also be collected at the Early Termination (ET) visit (if 
applicable) and may beanalyzed.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 51 23March 20186.10. Optional Genomic Sample
 
 
 
 
 
 
6.11. Safety Assessments
Safety  will be evaluated throughout the study . Refer to Table 6-1fora schedule of assessments.
6.11.1. Electrocardiogram Assessment
Subjects should rest quietly  in the supine position for a minimum of 10 minutes prior to each 
scheduled ECG acquisition and should remain in that position until the recording is complete.
There shoul d be no environmental distractions ( including TV, radio, video games, and 
conversation
) while the subjects are resting prior to and during the recordings. 
Electrocardiograms will be recorded using the site’s standard ECG equipment . All ECGs will be 
obtained using instruments that analy ze data using the same algorithms and produce the same 
data for interpretation. Electrode placement will be performed according to the method of 
Wilson, Goldberger, and Einthoven with a check to confirm that the aVR lea d is not inverted.
The investigator or other qualified individuals at the study  center will review ECGs to assess for 
changes in ECG intervals and morphology  as compared with pretreatment ECGs. ECG interval 
measurements output b y the machine will be used f or bedside safet y monitoring.
Collection of additional ECGs for routine safet y monitoring at additional time points or day s is at 
the discretion of the investigator based on GCP .
CCI
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 52 23March 20186.11.2. Physical Examination
Physical examinations conducted throughout the study  will be a complete phy sical examination 
or a s ymptom -directed phy sical examination ,as outlined in Table 6-1. The complete phy sical 
examination conducted at 
screening will also include the following assessments:
Review medical history , including history  of al lergies, prior and current use of nicotine or 
nicotine -containing products, alcohol and illegal drug use ,and prior (within 30 day s) and 
current medication use
6.11.3. Vital Signs
Vital sign measurements include blood pressure, pulse, respiration rate, and tempera ture and 
should be taken once subjects have been se ated or in the supine position. Subject position for 
measurement should be kept consistent throughout the study. Refer to Table 6-1forvital signs 
collection time points.
6.11.4. Body Mass Index
Height and weight will be collected at 
screening for calculation of BMI for inclusion criteria.
6.11.5. Clinical Laboratory Tests/Assessments
Blood and urine samples for safety  evaluations will be collected throughout the study  as outlined 
in Table 6-1.
6.11.5.1. Blood 
Sampling
Blood samples will be collected for the following laboratory  anal yses:
Hematolog y: CBC with differential
Serum chemistry (fasting): alkaline phosphatase, AST, AL T,GGT total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calc ium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, total cholesterol, HDL, LDL, 
triglycerides, and am ylase (reflex lipase testing is performed in subjects with total amylase
1.5  U L N).
HIV- 1/2, HBVsA g,andHCV -Ab testing (Screening on ly)
Coagulation 
(PT, PTT, IN R; Screening and FU Visit onl y)
α-fetoprotein test (Screening on ly)
Serum pregnancy test (females of childbearing potential only)
FSH  (Female subjects ≤ 54 years old with amenorrhea > 12 months, Screening only)
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 53 23March 20186.11.5.2. Urine Samples
Urine samples will be collected for urinal ysis and alcohol and drug screen assessments.
6.11.6. Creatinine Clearance
Weight will be collected at Screening to calculate creatinine clearance (eGFR) for inclusion 
criteria.
6.11.7. Adverse Events/Concomitant Medications/Protocol Restrictions
Evaluation for AEs, review of concomitant medications, and review of protocol restrictions will 
occur at the times shown in Table 6-1. See Section 7for more information regarding AEs and 
Sections 
4.3and5.7.1 for more information about concomitant medications.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 54 23March 20187. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An AE is an y untoward medical occurrence in a clinical study subj ect administered a study  drug , 
which does not necessarily  have a causal relationship with the treatment. An AE can ,therefore ,
be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated with the 
use of a study  drug , whether or not considered re lated to the study  drug . Adverse events may also 
include pre -or posttreatment complications that occur as a result of protocol -specified
procedures, overdose ,drug abuse/misuse reports , or occupational exposure .Preexisting events 
that incre ase in severit
y or change in nature during or as a consequence of participation in the 
clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transf usion. 
The condition that ledto the procedure may  be an AEand must be reported.
Preexisting diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrenc e has not occurred (eg ,hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.8.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and that is not related to a protocol- associated procedure is 
not an AE. It is considered to be pre existing and should be documented on the medical 
history  eCRF.
7.1.2. Serious Adverse Events
A SAE is defined as 
an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
Inpatient hospitalization or prolongation of existing hospitalization
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 55 23March 2018Persist ent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction ;such events may not be immediately  life-
threatening or result in death or hospitalization but may  jeopardize the subject or may  require 
intervention to prevent one of the other outcomes constituting SAEs. Medical and scientific 
judgment must be exercised to determine whether such an event is a reportable under 
expedited reporting rules. 
Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edicall y important e vent and subject to expedited reporting 
requirements.
7.1.2.1. Protocol -Specific Serious Adverse Event Instructions
Protocol -specific SAEs: In this study , is to be considered medically  important and ,therefore,
“serious.”
Protocol -specific SAE reporting exemptions: 
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified s ubinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to study  
drug using clinical judgment and 
the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug. For SAEs, an 
alternative causality  must be provided (eg, pre existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the study  drug .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures (eg, venipun cture) .
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 56 23March 20187.2.2. Assessment of Severity
AE severi ty should be recorded and graded according to the modified GSI Grading Scale for
Severity of Adverse Events and Laboratory Abnormalities (se eAppendix 4for
moreinformation). For AEs associated with laboratory abnormalities, the event should be graded 
on the basis of the clinical severit y in the context of the under lying conditions; this may ormay
not be in agreement with the grading of the laboratory abnormalit y
.
The distinction between the seriousness and the s everit yof an adverse event should be noted.
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensit y, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory abnormalities, the event should be graded on the basis of the 
clinical severi ty in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the labor atoryabnormalit y .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
7.3.1. Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medicatio n, the following t ypes ofevents 
should be reported on the case report form (CRF/eCRF): all SAEs and AE related to protocol -
mandated procedures.
7.3.1.1. Adverse Events
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until 30 day s after last administration of study  drug must be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the AE is stable, if possible. Gilead 
Sciences may  request that certain AEs be followed bey ond the protocol defined follow up period.
7.3.1.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of th e 
study , including the protocol -required post treatment follow -up period, must be reported to the 
CRF/eCRF database and Gilead DSPH as instructed. This also includes any  SAEs resulting from 
protocol -associated procedures performed after informed consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 day s of the 
last dose of study  drug, regardless of causalit y, should also be reported.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 57 23March 2018Investigators are not obligated to activel y seek SAEs after the protocol d efined follow up period, 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of study drug, he/she should promptly  document and 
report the event to Gilead DSPH.
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline.
7.3.1.3. Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there tran smit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper SAE reporting form and submit 
within 24 hours as described below.
Gilead DSPH:Fax:
E-mail:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessar y.
For fatal or lif e-threate ning events, copies of hospital case reports, autop syreports, and other 
documents are also to besubmitted bye-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identificatio n, 
maintaining thetraceabilit y
of a document to the subject identifiers.
Additional information maybe requested t o ensure the timely completion of accurate safe ty 
reports.
Anymedications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
7.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials D irective (2001/20/EC) and relevant updates, and 
other countr y-specific legislation or regulations, Gilead ma yberequired to expedite to
PPD
PPD
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 58 23March 2018worldwide regulatory agencies reports of SAEs, serious a dverse drug reactions (SADRs ), or 
suspected unexpected s eriou s
adverse r eactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or aspecified designee will notify worldwide regulatory  
agencies and the relevant IECin concerned Member States of applicable SUSARs as outlined in 
curre nt regulations.
Assessment of e xpectedness for SAEs will be determined by Gilead using reference safety  
information specified in the IB or relevant local label as applicable.
All invest igators will receive a safe ty letter notifying them of relevant SUSAR r eports associated 
with any studydrug. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional polic y.
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , and urinal ysis) independent of the 
underly ingmedical condition that require medical or surgical intervention or lead to 
investigational medicinal product interruption or discontinuation must be recorded as an AE, 
aswell as an SAE, if applicable. In addition, laboratory  or other abnor mal assessments (eg, ECG, 
X-rays, vital signs) that are associated with signs and/or sy mptoms must be recorded as an AE or 
SAE if they  meet the definition of an AE (or SAE) as described in Sections 7.1.1 and7.1.2. If the 
laboratory  abnormality  is part of 
a syndrome, record the sy ndrome or diagnosis (ie, anemia) not 
the laboratory  result (ie, decreased hemoglobin).
Severity  should be recorded a nd graded according to the Gilead Grading Scale for Severity  of 
Adverse Events and Laboratory  Abnormalities as desc ribed in Appendix 4. The GSI Grading 
Scale for Severity  of Adverse Events and Laboratory  Abnormalities has been modified to be 
more appropriate for healthy
 volunteers and patients with inflammatory diseases (eg, rheumatoid 
arthritis, asthma, psoriasis). Fo r AEs associated with laboratory  abnormalities, the event should 
be graded on the basis of the clinical severit y in the context of the underl ying conditions; this 
may or may  not be in agreement with the grading of the laboratory  abnormality .
7.6. Toxicity Management 
Treatment -emergent toxicities will be noted by the investigator and brought to the attention of 
the Gilead medical monitor (MM), who will have a discussion with the investigator and decide 
the appropriate course of action. Whether or not considered treatm e
nt-related, all subjects 
experiencing AEs must be monitored periodically until symptoms subside, anyabnormal Grade 3 
or 4 clinically  significant laboratory  abnormalities should be managed as outlined in Appendix 2.
Any questions regarding toxicity  management should be directed to the Gilead MM.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 59 23March 20187.7. Study Specific Stopping Criteria
Study  drug dosing of a cohort will be suspended and, based on full review of the clinical data by  
the MM and in discussion with the investigator, may  be halted when:
2 healthy control subjects dosed with GS-9674 within a cohort experience elevations in liver 
function tests of ALT and/or AST > 5 x the upper limits of normal (UL N); or ALT > 3 x 
ULN and total bilirubin > 2 x UL N, confirmed b y immediate repeat testing.
2 hepatic im pairment subjects dosed with GS -9674 within a cohort experience elevation of 
baseline liver function tests of AL T and/or AST > 3 x baseline; or AL T > 2 x baseline and 
total bilirubin > 2 x baseline.
1 subject experiences a SAE possibly  related to the study drug
The sponsor unilaterall y requests it.
Decisions to reinitiate the study  will be made in consultation with the sponsor and pending a 
safet y review.
7.8. Special Situations Reports
7.8.1. Definitions of Special Situations
Special situation reports includ e all repo rts of medication error, abuse, misuse, overdose, reports 
of AEs associated with product complaints, occupational exposure with an AE, pregnancy  
reports regardless of an associated AE , and an AE in an infant following exposure from 
breastfeeding .
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  that is above the maximum recommended dose 
as per protocol or in the product labeling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 60 23March 2018Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
7.8.2. Instructions for Reporting Special Situations
7.8.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  drug and throughout the stud y, including the poststud y drug follow - up pe riod, 
to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy . 
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must b e reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Section 7.3. Furthermore, any  SAE occurr ing as an adverse pregnancy  outcome post study  must 
be reported to Gilead DSPH .
The subject should receive appropriate monitoring and care until 
the conclusion of the pregnancy . The outcome should be reported to Gilead DSPH using the 
pregnancy  outcome repo rt form. If the end of the pregnancy  occurs after the study  has been
completed, the outcome should be reported directly  to Gilead DSPH byemailing
 or faxing  
Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the pregnancy should 
continue until its conclusion. I f the end of the pregnancy  occurs after the study  has been 
completed, the outcome should be reported directly  to Gilead DSPH by  faxing  
or email ing  
Refer to 
Appendix 3, Pregnancy  Precautions, Definition for Female of Chil dbearing Potential, 
and Contraceptive Requirements.
7.8.2.2. Reporting Other Special Situations
All special situations reports (SSRs) will be recorded in the CRF/eCRF database within the 
timelines outlined in the CRF/eCRF completion gui deline.
Electronic Special Situations Report (eSSR) Reporting Process
PPD
PPD
PPD
PPD
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 61 23March 2018Site personnel record all SSR data in the eCRF database and from there transmit the SSR 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for a ny reason it is not possible to record the SSR information electronically, i.e., the eCRF 
database is not functioning, record the SSR on the paper serious adverse event reporting form 
and submit within 24 hours to:
Gilead DSPH:E-mail:
Fax:
As soon as it is possible to do so, any  SSR reported via paper must be transcribed into the eCRF 
Database according to instructions in the eCRF completion guidelines.
If an SSR has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse” but may  be more appropriately documented as a protocol deviation.
Refer to 
Section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported a s AEs or SAEs 
at the same time using the AE CRF/ eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
PPD
PPD
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 62 23March 20188. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Obj ectives
The primary objective ofthisstudy is as follows:
To evaluate the singl e-dose PK of GS -9674 in subjects with normal hepatic function, or mild, 
moderate and severe hepatic impairment
The secondary objectiv es of thisstudy areas follows:
To evaluate the safe tyand tolerability of GS-9674 single dose administration in subjects with 
normal hepatic function, or mild, moderate, and severe hepatic impairment
To evaluate FXR activation by GS-9674 asmeasured byPD markers in sub jects with normal 
hepatic function, or mild, moderate and severe hepatic impairment
8.1.2. Primary Endpoint
The primary endpoints are single dose plasma PK parameters of GS-9674 AUC last, AU Cinf, and 
Cmax. Additional PK parameters calculated include: %AU Cexp, Clast, Tmax, Tlast, λz, CL /F,Vz/F, 
and T 1/2as appropriate.
8.1.3. Secondary Endpoint
The secondary  endpoints are the incidences of AEs and laboratory  abnormalities, physical 
examinations, vital signs, ECGs, and PD markers including but not limited to FGF19 and C4.
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. Safety
The Safet y Analysis Set will include all enrolled subjects who received at least 1dose of study  
drug. Subjects who received treatment other than that to which they  were assigned will be 
analyzed according to the treatment received.
8.2.1.2.
Pharmacokinetics
The PK Anal ysis Set for GS-9674 will include all enrolled subjects who received at least 1 dose 
of GS-9674 and had at least 1 non- missing PK concentration data reported by  PK lab for each 
respective anal yte.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 63 23March 20188.2.1.3. Pharmacod ynamics
Each PDanalysis set will include all enrolled subjects who received at least 1 dose of studydrug 
and have at least 1 non -missing PD value for each respective PD parameter.
8.3. Data Handling Conventions
For summary statistics, PK concentration values below the limit of quantitation (BLQ) will be 
treated as zero at predose and one-half of the lower limit of quantitation (LLOQ) for postdose 
time points.
Laboratory data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit 
minus or plus one significant digit, respective ly(eg, if the result of a continuous laboratory test is
<20, a value of 19 will be assigned; if the result of a continuous laboratory test is < 20.0, a value 
of 19.9 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. As this study is of short 
duration, it is anticipated that missing data will be minimal. In general, values for missing data 
will not be imputed. However, a missing pretreatment laboratory result would be treated as 
normal (ie., notoxicity grade) for the laboratory abnormalit ysummar y.
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be su mmarized and descriptive statistics will be 
provided.
8.5. Interim Analysis
There is no formal interim analy sisinthisstudy.
8.6. Safety Analysis
All safe ty data collected on or after the date that study drug was first administered up to the date 
of last dose of stud ydrug plus 30 da ys will be summarized by hepatic function group (according 
to the stud ydrug received) using safe ty analysis set.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug data will be generated from the study  drug
administration page in eCRF. Exposure data will be listed.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 64 23March 20188.6.2. Adverse Events
Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). S ystem Organ Class (SOC), Hig h-Level Group Term (HLGT), High- Level Term 
(HLT), Preferred Term (PT), and
Lower-Level Term (LLT) will be attached to the clinical 
database.
Adverse event data will be listed by subject.  Treatmen t-emergent AE (TEAE), Serious TEAE, 
and TEAE leading to discontinuation of treatment will be summarized by hepatic function group, 
system organ class, and preferred term using the current version the Medical Dictionary for 
Regulatory Activities (MedDRA).
8.6.3. Laboratory Evaluations
Listings of individual subject laboratory  results will be provided.  Laboratory results and change 
from predose values for selected lab tests will be summarized by  hepatic function group at 
scheduled visits. The incidence of treatment -emergent graded laboratory  abnormalities will be 
summarized by  hepatic function group.
8.6.4. Other Safety Evaluations
Vital signs and ECG data will be listed by  subject and visit, and summarized by  hepatic function 
group and visit.
8.7. Pharmacokinetic Analysis
Plasma concentrations and PK parameters will be listed and summarized for GS -9674   using 
descri ptive statistics by hepatic function group(normal and mildly impaired, moderate
ly 
impaired, or severe ly impaired) within cohort.
In addition, an ANOVA model with hepatic function group as a fixed effect will be fitted to the 
natural logarithmic transforma tion of PK parameters (AUC last, AU Cinf,and Cmax)for GS-9674 for 
each cohort. T wo-sided 90% CI s will be calculated for the ratios of G LSM of PK parameters for 
GS-9674 between mild, moderate or severe hepatic impairment group and the control (normal 
hepatic function) group. If the upper bound of the two- sided 90% CI s of the G LSM ratio for 
AUC last, AU Cinf, and C max is smaller than 2.0, the null hy pothesis that subjects with mild, 
moderate or severe hepatic impairment exhibit average PK paramet er increa ses of at least 100% 
for GS-9674 compared with subjects with normal liver function will be rejected.
GS-9674 percent protein binding will be summarized by hepatic function group and data for 
individual subjects will be presented in a listing. Unbound PK parameters such as C Lu/F, and 
Vzu/F will be c alculated and summarized by hepatic function group.  Relationships between 
measures of hepatic function (ie, CPT score, serum albumin, total bilirubin, prothrombin time 
and INR) and GS-9674 PK parame ters will be evaluated.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 65 23March 20188.8. Pharmacodynamics Analysis
Pharmacodynamics data will be listed and summarized using descriptive statistics by hepatic 
function within and across cohorts.
8.9. Pharmacokinetic s and Pharmacodynamics Analysis
The PK/PD relationship may  be explored using a graphic approach and correlation coefficients 
as appropriate. 
8.10. Sample Size
For each cohort, with 16 (8 per group) evaluable subjects, the estimated upper limit of one- sided
95%
CIof the GLSM ratio of (mild, moderate or severe) hepatic imp aired group vs control 
(normal hepatic function), with regards to AU Clast, AU Cinf, and C max, would be less than 200% 
with ≥ 88% probabilit y, if the estimated GLSM ratio were 1.0. This is assuming a SD of no more 
than 0.463 on a natural logarithm scale, sup porte d by previous Gilead study GS -US-402-1851. 
With 25% overage, a total sample size of 60 subjects (10 per group, 20 per cohort) will be 
required.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 66 23March 20189. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  isconducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and South 
Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, "Protection of Human Subjects", and 21 CFR, part 56, "Institutional Review Boa rds".
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 
"Financial Disclosure b y Clinical I nvestigators", providing documentation of their financial 
interest or arrangements with Gilead, or proprietary interests in the study  drug under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study. The investigator and subinvestigator agree to notify  Gilead of any  
change in reportable interests during the stu dy and for 1 y ear following completion of the study . 
Study  completion is defined as the date when the last subject completes the protocol -defined 
activities.
9.1.2. Institutional Review Board/Independent Ethics Committee Review and 
Approval
The investigator (or Sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/EC. The investigator will not begin an y stud y subject activities until 
approval from the IRB/IEC has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/EC any  modifications made to the protocol or any  accompany ing material to be 
provided to the subject after initial I RB/EC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 67 23March 20189.1.3. I nformed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking a ny study -related procedures. The 
investigator must use the most current IRB/EC -approved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject or the subj ect’s legally  authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by  local 
requirements. The consent form will inform subjects about genomic testing and sample retention, 
and their right to receive clinically  relevant genomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of bir th, another 
unique identifier (as allowed by local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, I RB/EC, or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject i dentity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions or in accordance
with local regulations. NOTE: The investigator must keep a screening log showing codes, names, 
and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will 
be processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF/eCRF, the study  drug, and an y other study information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agent s directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the
disclosure b y any employee or agent of the stud y site to any third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. Th ese documents should 
be classified into at least the following 2 categories: (1)investigator’s study file and (2) subject 
clinical source documents.
The investigator’s study file will contain the protocol/amendments, CRF and query forms, 
IRB/EC and govern mental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 68 23March 2018The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender)
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria)
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number)
Study  discussed and date of informed consent
Dates of all visits
Documentation that protocol specific procedures were performed
Results of efficacy  parameters, as required b y the protocol
Start and end date s(including dose regimen) of study  drug , including dates of dispensing and 
return
Record of all AEs and other safety  parameters (start and end date s, and including causality  
and severit y)
Concomitant medication (including start and end date
s, dose if relevant , and dose changes)
Date of stud y completion and reason for earl y discontinuation, if it occurs
All clinical study  documents must be retained b y the investigator until at least 2 yearsor 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no applica tion is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified b y regulator y requirements, b y local regulations, or by an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
locati on, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the i nvestigator and Gilead to store 
these records secure ly away  from the site so that they  can be returned sealed to the investigator 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 69 23March 2018in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject enrolled , an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. The eCRF should 
be completed on the day  of the subject visit to enable the s ponsor to perform central monitoring 
of safet y data , whenever possible . The Eligibility  Criteria eCRF should be completed only  after 
all data related to eligibility  have been received and the subject has been enrolled. Subsequent to 
data entry , a stud y monitor wi ll perform source data verification within the electronic data 
capture ( EDC )system. Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem. Prior to database lock (or any  interim time points as described in the 
clinical data management plan), the investigator will use his/her 
login credentials to confirm that 
the forms have been reviewed, and that the entries accuratel y reflect the information in the 
source documents. The eCRF capture sthe data required per t he protocol schedule of events and 
procedures. System -generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  the monitor or internal Gilead staff who routinely  review the 
data for completeness, co rrectness, and consistency. The site coordinator is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason for the update (eg ,data entry  
error). At the conclusion of the study , Gilead will provide the site with a read -only archive copy  
of the data entered b y that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Study Dr ugAccountability and Return 
Where possible, 
Gilead recommends that used and /orunused study  drug supplies be destro yed at 
the site . If the site has an appropriate SOP for drug destruction as determined by  Gilead Sciences, 
the site may  destroy  used (empty or partiall y empty ) and /orunused study  drug supplies in 
accordance with th atsite’s approved SOP. A cop y of the site’s IMP Disposal SOP or written 
procedure (signed and dated by  PI or designee) will be obtained for Gilead’s site files. If the site 
does not have acceptable procedures in place for drug destruction, study  drug supplies can be 
returned to the designated depot . The study  monitor will provide instructions for the return. 
Ifstudy  drug is destro yed on site, the i nvestigator must maintain accura te records for all study  
drug destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug . Upon study  completion, 
copies of the study  drug accountability  reco rds must be filed at the site. Another copy  will be 
returned to Gilead .
For both options, the study  monitor must first perform drug accountability during an on- site 
monitoring visit. Additionally , the stud y monitor will review study  drug supplies and assoc iated 
records at periodic intervals.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 70 23March 20189.1.8. Inspections
The investigator will make available all source documents and other records for this study to 
Gilead’s appointed stud y monitors, to IRB/EC,or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to IRB/EC in 
accordance with local requirements and receive documented IRB/EC approval before 
modifications may be implemented.
9.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agenc y. Gilead will ensure 
that the report meets the standards set out in the ICH Guideline for Structure an d Content of 
Clinical Study  Reports (ICH E3). Note that an abbreviated report may  be prepared in certain 
cases. 
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed un der this 
protocol, eg ,attendance at i nvestigator's m eetings. If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to federal and state agencies any  
expenses paid or reimbursed for such services, includin g any clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completenes s, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 71 23March 2018verify  the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected throu gh an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the i nvestigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the Gilead medical monitor immediately . The i nvestigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the ef fective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the Sponsor and the investigator reserve the right to terminate the study at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and ECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 72 23March 201810. REFERENCES
Afzali A, Berry  K, Ioann ou GN. Excellent posttransplant survival for patients with nonalcoholic 
steatohepatitis in the United States. L iver Transpl 2012;18 (1):29 -37.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Dietrich P, Hellerbrand C. Non- alcoholic fatt y liver disease, obesity and the metabolic s yndrome. 
Best practice & research 2014;28 (4):637-53.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non -alcoholic fatty  liver disease. 
QJM 2010;103 (2):71-83.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the 
strongest predictor for disease -specific mortality  in NAFLD after up to 33 y ears 
of follow -up. Hepatology 2015;61 (5):1547 -54.
Faramawi MF, Wildman RP, Gustat J, Rice J, Abdul Kareem MY. The association of the 
metabolic sy ndrome with QTc interval in NHANES III. Eur J Epidemiol 2008;23 
(7):459-65.
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial 
fibrillation: the Framingham study . N Eng l J Med 1982;306 (17):1018 -22.
Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non -alcoholic steatohepatitis. Clin 
Chim Acta 2011;412 (15- 16):1297-305.
Murakami T, Takigawa N, Ninomiy a T, Ochi N, Yasugi M, Honda Y, et al. Effect of AZD1480 
in an epidermal growth factor receptor -driven lung cancer model. Lung Cancer 
2013.
Nakamoto K, Takay ama F, Mankura M, Hidaka Y, Egashira T, Ogino T, et al. Beneficial Effects 
of Fermented Green Tea Extract in a Rat Model of Non -alcoholic Steatohepatitis. 
Journal of clinical biochemistry  and nutrition 2009;44 (3):239-46.
Ong JP, Younossi ZM. Epidemiology  and natural history  of NAFLD and NASH. Clin L iver Dis 
2007;11 (1):1 -16, vii.
Pugh RNH, Murray -Lyon IM, Dawson J L, Pietroni MC, Williams R. Transection of the 
Oesophagus for Bleeding Oesophageal Varices. Br J Surg 1973;60 (8):646-9.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in 
NAFLD/NASH. Free radical research 2013;47 (11):869 -80.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 73 23March 2018U.S. Department of Health and Human Services Food and Drug Administration Center for Drug 
Evaluation and Research (CDER); Center for Biologics Evaluation and Research 
(CBER). Guidance for Industry . Pharmacokinetics in Patients with I mpaired 
Hepatic Function: Study  Design, Data Anal ysis,and I mpact on Dosing and 
Labeling.  May , 2003.
Vernon G, Baranova A, Younossi ZM. S ystematic review: the epidemiology  and natural history  
of non- alcoholic fatty  liver disease and non -alcoholic steatohepatitis in adults. 
Aliment Pharmacol Ther 2011;34 (3): 274-85.
Voulgari C, Tentolouris N, Papadogiannis D, Moyssakis I, Perrea D, Ky riaki D, et al. Increased 
left ventricular arrh ythmogenicity  in metabolic s yndrome and relationship with 
myocardial performance, risk factors for atherosclerosis, and low -grade 
inflammation. Metabolism: clinical and experimental 2010;59 (2):159 -
65.
Wanless I R, Lentz JS. Fatty  liver hepatitis (steatohepatitis) and obesity : an autopsy  study  with 
analysis of risk factors. Hepatology  1990;12 (5):1106-10.
Williams CD, Stengel J, Asike M I, Torres DM, Shaw J, Contreras M, et al. Prevalence of 
nonalcoholic fatt y liver disease and nonalcoholic steatohepatitis among a largely 
middle -aged population utilizing ultrasound and liver biopsy : a prospective study . 
Gastroenterology  2011;140 (1):124-31.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly  growing 
indication for liver transplantation in patients with hepatocellular carcinoma in the 
U.S. Hepatology  2014;59 (6):2188-95.
Yeh MM, Brunt EM. Pathological features of fa tty liver disease. Gastroenterology  2014;147 
(4):754-64.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 74 23March 201811. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Management of Clinical and Laboratory Adverse Events
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. Gilead Grading Scale for Severity of Adverse Ev ents and Laboratory Abnormalities
PPD
PPDG$-9674 
Protocol GS-US-402-3885 Final 
Gilead Sciences , Inc. Amendment 2 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the 
Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects with Normal and 
Impaired Hepatic Function 
GS-US-402-3885, Amendment 2, 23 March 2018 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approvaL 
Medical Monjtor 
Date [ 
Signature 
INVESTIGATOR STATEMENT 
[ have read the protocol , including all appendices , and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences , Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFlDENTIAL Page 75 23 March 2018 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 76 23March 2018Appendix 2. Management of Clinica l and Laboratory Adverse Events
L l IL_ _______ c._a_d•_4 ______ __J 
Repeat lab to confintt toxicity pade 
1 
If confirmed and possibly uprobably 
related to study drug, dismntinue study 
drug dosing permanently and fo&w at 
pe1iA>dic inteJV als at least weeldy "Wttil a 
to baseline or is: otketwise 
e>plained 1 
Study Drug may be continued without dose 
irderruption for a 3 
or 41aboratoty abnormality(eg. Grade 4 CK after 
strenuous exercise, or 
elevation, or blood in urine due to menses or that 
can be medically manage <!I or a clinical event 
considered unrelated to study drug 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 77 23March 2018Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this stud
y, a female born subject is considered of childbearing potential 
following the initiation of puber ty (Tanner stage 2) until becoming post -menopausal, unless 
permanent ly sterile or with medically documented ovarian failure.
Women are considered to be in a postmenopausal state when they are> 54 ye ars of age with 
cessation of previously occurring menses for > 12 months without an alternative cause. In 
addition, women of a ny age with amenorrhea of >12 months may also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
andthey are not using hormonal contraception or hormonal replacem enttherap y .
Permanent sterilization includes h ysterectom y, bilateral oophorecto my, or bilateral 
salpingectomy in a female subject of a nyage.
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a. S tudy Drug Effects on Pregnancy and Hormonal Contraception
GS-9674 has not yet been studied in pregnant women. There are no preclinical data available to 
determine whether GS-9674 is teratogenic or fetotoxic in early human pregnan cy. There are 
insufficient data to exclude the possibility ofaclinically relevant interaction between GS -9674
and hormonal cont raceptives th
at result in reduced contraception efficac y. Therefore, the use of 
hormonal contraception with GS-9674 is not recommended.
Therefore, in the GS-9674 clinical studies, women of childbearing potential must use a high ly 
effectiv econtraceptive m easure or choose continuous heterosexual abstinence from intercourse 
from screening throughout the study period and for 30 day s after last dose of GS -9674 .
Please refer to the latest version of the investigator’s brochure for additional information.
b. Contraceptio n Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of high lyeffective 
contraceptive measures. They must have a negative serum pregnancy test at Screening and a 
negative pregnancy test on the Baseline/Day -2 visit prior to randomization.  At minimum, a 
pregnancy test will be performed at the end of relevant s ystem exposure.  In the event of a
delay ed menstrual period (over one month between menstruations), a pregnancy  test must be 
performed to rule out pregnancy .  This is even true for women of childbearing potential with 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 78 23March 2018infrequent or irregular periods. Female subjects must agree to one of the following from 
Screening until 30 day s after last dose of GS-9674.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only when it is in line with the subject’s preferred and usual 
lifest yle.
Or
Consistent and correct use of 1 of the following methods of b
irth contr ol listed below.
Intrauterine device (IUD) with a failure rate of <1% per ye ar
Tubal sterilization
Essure micro- inser t system (provided confirmation of success 3 months after procedure)
Vasecto my in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after last dose of GS-9674 .
3)Contraception Requir ements for Male Subjects
It is theoretical ly possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and for 90 da y s after last 
dose of GS-9674 .
Male subjects must agree to avoid sperm donation from baseline throughout the study period and 
for 90 da ys after last dose of GS -9674 .
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, s ymptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator and discontinue study  drug immediatel y,if 
they become pregnant at any  time during the study, or if they  become pregnant within 30 day s 
(90 day s of partner of male subject) of last study  drug dose. Subjects whose partner has become 
pregnant or suspects she is pregnant during the study  must report the information to the 
investigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are 
outlined in Section 7.3.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 79 23March 2018Appendix 4. Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1 –21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 80 23March 2018HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months# 1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 81 23March 2018HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66ULN 1.66 to 2.33ULN 2.33 to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. P lease follow the Gilead convention of grading 
any result within the LLN and ULN a 0.  
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 82 23March 2018CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to55mg/dL
2.20 to3.03 mmol/L30 to40mg/dL
1.64 to2.20 mmol/L30mg/dL
1.64 mmol/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30mg/dL
1.7 mmol/L
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 83 23March 2018CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to7.8mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1 mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0mg/dL
1.36 to < 1.49 mmol/L 5.5mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0mg/dL toLLN 2.5 to < 3.0 mg/dL 2.0 to2.5mg/dL 2.0mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 84 23March 2018CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5mg/dL
0.31 to 0.47 mmol/L1.0mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmol/L1.5mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmol/L1.5mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 85 23March 2018CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year    
Infant  < 1 Year1.5mg/dL toLLN
87 μmol/L to LLN1.0 to1.5mg/dL
57 to87 μmol/L0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
N/A 1.0mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 86 23March 2018CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs.  Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 87 23March 2018ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 88 23March 2018URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999mg/24h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499 to799mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be ass igned Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (eg, the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 89 23March 2018CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140– 159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 90 23March 2018CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 91 23March 2018RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 92 23March 2018SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerCom plete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 93 23March 2018GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervent ion indicatedLife-threatening reduction in 
oral intake
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 94 23March 2018GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform us ual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 95 23March 2018NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than min imal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference wi th 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 96 23March 2018NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 97 23March 2018NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolong ed, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 98 23March 2018MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 99 23March 2018SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 100 23March 2018INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basi c self -care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 101 23March 2018ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew  onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social &
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-9674
Protocol GS -US-402-3885 Final
Gilead Sciences, Inc. Amendment 2
CONFIDENTIAL Page 102 23March 2018GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHem orrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional act ivitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transpor tation, pursuing a hobby, etc.